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A B S T R A C T
Background
Dietary fluoride supplements were first introduced to provide systemic fluoride in areas where water fluoridation is not available. Since
1990, the use of fluoride supplements in caries prevention has been re-evaluated in several countries.
Objectives
To evaluate the efficacy of fluoride supplements for preventing dental caries in children.
Search methods
We searched the Cochrane Oral Health Group’s Trials Register (to 12 October 2011), the Cochrane Central Register of Controlled
Trials (CENTRAL) (The Cochrane Library 2011, Issue 3), MEDLINE via OVID (1950 to 12 October 2011), EMBASE via OVID
(1980 to 12 October 2011), WHOLIS/PAHO/MEDCARIB/LILACS/BBO via BIREME (1982 to 12 October 2011), and Current
Controlled Trials (to 12 October 2011). We handsearched reference lists of articles and contacted selected authors.
Selection criteria
We included randomised or quasi-randomised controlled trials comparing, with minimum follow-up of 2 years, fluoride supplements
(tablets, drops, lozenges) with no fluoride supplement or with other preventive measures such as topical fluorides in children less than
16 years of age at the start. The main outcome was caries increment measured by the change in decayed, missing and filled tooth
surfaces (DMFS).
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Data collection and analysis
Two review authors, independently and in duplicate, assessed the eligibility of studies for inclusion, and carried out risk of bias assessment
and data extraction. In the event of disagreement, we sought consensus and consulted a third review author. We contacted trial authors
for missing information. We used the prevented fraction (PF) as a metric for evaluating the efficacy of the intervention. The PF is
defined as the mean caries increment in controls minus mean caries increment in the treated group divided by mean caries increment
in controls. We conducted random-effects meta-analyses when data could be pooled. We assessed heterogeneity in the results of the
studies by examining forest plots and by using formal tests for homogeneity. We recorded adverse effects (fluorosis) when the studies
provided relevant data.
Main results
We included 11 studies in the review involving 7196 children.
In permanent teeth, when fluoride supplements were compared with no fluoride supplement (three studies), the use of fluoride
supplements was associated with a 24% (95% confidence interval (CI) 16 to 33%) reduction in decayed, missing and filled surfaces
(D(M)FS). The effect of fluoride supplements was unclear on deciduous or primary teeth. In one study, no caries-inhibiting effect was
observed on deciduous teeth while in another study, the use of fluoride supplements was associated with a substantial reduction in
caries increment.
When fluoride supplements were compared with topical fluorides or with other preventive measures, there was no differential effect on
permanent or deciduous teeth.
The review found limited information on the adverse effects associated with the use of fluoride supplements.
Authors’ conclusions
This review suggests that the use of fluoride supplements is associated with a reduction in caries increment when compared with no
fluoride supplement in permanent teeth. The effect of fluoride supplements was unclear on deciduous teeth. When compared with
the administration of topical fluorides, no differential effect was observed. We rated 10 trials as being at unclear risk of bias and one at
high risk of bias, and therefore the trials provide weak evidence about the efficacy of fluoride supplements.
P L A I N L A N G U A G E S U M M A R Y
Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing tooth decay in children
Tooth decay (dental caries) can cause pain and lead to loss of teeth. In most developed countries, the prevalence of dental caries
has decreased in the past 30 years in child populations. Nevertheless, some individuals or populations experience an increased caries
challenge and are considered as being at ’high caries risk’.
Fluoride is a mineral that prevents tooth decay. Fluoride can be administered in different ways, either topically (toothpastes, mouth
rinses, varnishes, gels) or systemically (fluoride supplements, fluoridated water, salt). Today, posteruptive (topical) preventive effect
of fluoride is considered as being more important than the pre-eruptive (systemic) effect. Topical fluorides have been shown to be
highly effective and the use of fluoride-containing toothpastes is now almost universal. When daily toothbrushing with a fluoridated
toothpaste is not carried out or when the caries-risk is increased, additional sources of fluoride could be recommended.
Fluoride supplements are administered in the formof lozenges, tablets or liquids. In this review, we only considered fluoride administered
through supplements.
The review indicates that in schoolchildren (greater than 6 years of age), fluoride supplements when compared with no fluoride
supplementation had a preventive effect on caries in permanent teeth. There was no differential effect between fluoride supplements
and topical fluorides for preventing dental caries. Many of the studies included in the review had been conducted at a time when topical
fluorides were not widely used. There is thus a lack of evidence from the review to make actual good recommendations. Today, the
effect of fluoride supplements in children using fluoride toothpastes on a regular basis would probably be limited.
In the review, no conclusion could be reached about the effectiveness of fluoride supplements in preventing tooth decay in young
children (less than 6 years of age) with deciduous teeth. Moreover, insufficient evidence exists to show whether or not using fluoride
supplements in young children (less than 6 years of age) could mottle teeth (fluorosis), an effect of chronic ingestion of excessive
amounts of fluoride.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fluoride supplements compared to no fluoride supplement for preventing dental caries
Patient or population: Children and adolescents
Settings: Supplements administered at school or at home in North America, United Kingdom and Taiwan
Intervention: Fluoride supplements
Comparison: No fluoride supplement (placebo or no treatment)
Outcomes Illustrative comparative risks* Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk1,2 Corresponding risk1,2
No treatment Fluoride supplements
Caries increment on per-
manent tooth surfaces
(D(M)FS increment)
Follow-up: 24-36 months
The mean caries incre-
ment on permanent tooth
surfaces ranged across
control groups from
2.64 to 12.29 surfaces
The mean Caries incre-
ment on permanent tooth
surfaces in the interven-
tion groups ranged from
1.92 to 8.98 surfaces
0.24 [0.16;0.33] 1240
(3 studies)
⊕⊕⊕©
moderate
Random sequence gener-
ation, allocation conceal-
ment rated as unclear in
those 3 studies3,4
Caries increment on de-
ciduous tooth surfaces
(dmfs increment)
Follow-up: 24-36 months
The mean caries incre-
ment on deciduous tooth
surfaces in the control
group was 8.35 surfaces
The mean caries incre-
ment on deciduous tooth
surfaces in the interven-
tion groups ranged from
1.55 to 4.1 surfaces
0.73 [0.46, 0.99] 115
(1 study)
⊕©©©
very low
Only one study with a
small sample size and
an important effect3 . Ran-
dom sequence genera-
tion, allocation conceal-
ment rated as unclear in
this study
Caries increment in per-
manent teeth
(D(M)FT increment)
Follow-up: 24-36 months
The mean caries incre-
ment in permanent teeth
ranged across control
groups from 0.52 to 5.64
teeth
The mean caries incre-
ment in permanent teeth
in the intervention groups
ranged from 0.32 to 3.83
teeth
0.29 [0.19, 0.39] 1208
(3 studies)
⊕⊕⊕©
moderate
Random sequence gener-
ation, allocation conceal-
ment rated as unclear in
those 3 studies3,4
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Caries increment in de-
ciduous teeth
(dmft increment)
Follow-up: 24-36 months
The mean caries incre-
ment in deciduous teeth
ranged across control
groups from 1.02
to 4.24 teeth
The mean caries incre-
ment in deciduous teeth
in the intervention groups
ranged from 0.89 to 2.02
teeth
0.46 [0.08, 0.83] 696
(2 studies)
⊕©©©
very low
Only two studies with
high heterogeneity. Confi-
dence interval, wide. Ran-
dom sequence genera-
tion, allocation conceal-
ment rated as unclear in
those 2 studies3
Fluorosis (adverse ef-
fect)
% of children with flu-
orotic teeth (quoted as
questionable to severe)
Follow-up: 55 months
32/212 = 15% 40/202=20% (APF once
a day)
43/197 = 22% (APF
twice a day)
Not estimable 611
(1 study)
⊕©©©
very low
Only one study. Fluoro-
sis evaluated on teeth that
erupted lately during the
study period. Random se-
quence generation, allo-
cation concealment rated
as unclear in this study3,4
*The basis for the assumed risk (mean caries increment values in control groups) and corresponding risk (mean caries increment values in intervention groups) is provided in footnotes
The relative effect (95% confidence interval) is evaluated by calculating the prevented fraction = mean caries increment in controls minus mean caries increment in the treated group divided
by mean caries increment in controls.
CI: Confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 DMFS/T: Number of tooth surfaces (S) or number or teeth (T) decayed, missing or filled due to dental caries
2 Caries increment = final DMFS/T minus baseline DMFS/T
3 Many studies have been excluded from the review due to a lack of information concerning the allocation process
4 Studies conducted at a time when the use of topical fluoride was limited. Today, the effect of fluoride supplements would be different
due to the widespread use of fluoridated toothpastes
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B A C K G R O U N D
Dental caries is a multifactorial disease due to “an imbalance in
physiologic equilibrium between toothmineral and biofilm fluid”.
Cariogenic bacteria can produce acids when they metabolise fer-
mentable carbohydrates. These acids dissolve the calcium phos-
phate mineral of the tooth enamel or dentin (this is deminerali-
sation). If the process is not halted, the carious lesion progresses
leading eventually to a cavity. Protective factors such as salivary
calcium, phosphate and proteins, salivary flow and fluoride in
saliva can prevent or reverse the carious process by inhibiting dem-
ineralisation or enhancing remineralisation (Featherstone 1999;
Fejerskov 2004).
Dental caries is a controllable disease and a public health problem
because it affects a large number of people around the world. The
prevalence of dental caries among adults is high and the disease
affects nearly 100% of the population. In most developed coun-
tries, the prevalence and severity of dental caries have decreased
in the past 30 years in child populations. The repartition of car-
ious lesions has changed with most disease now found in a small
number of children often characterised by a low socioeconomic
status. Exposure to fluoride is usually seen as the principal reason
for this caries decline together with improving living conditions
(Marthaler 2004; Petersen 2005).
Fluorides play a key role in the prevention and control of dental
caries. Initially, it was believed that fluoride had to be ingested to
increase intake of fluoride during tooth formation in order to im-
prove caries resistance. This paradigm of an important pre-erup-
tive preventive effect of fluoride has influenced caries prevention
and research during the last 50 years. Fluoride had to be taken
systemically through fluoridation of drinking water or ingestion
of supplements. In this context, the risk associated with ingestion
of fluoride in children was linked to acute and chronic toxicity of
fluoride. Caries prevention had to be balanced against increasing
dental fluorosis. The ’topical’ preventive effect of fluoride was, for
a long time, claimed to be minor compared with the ’systemic’
effect. The new paradigm emphasising on the posteruptive pre-
ventive effect of fluoride evolved based on research findings con-
ducted in the 1970s. Laboratory studies showed that fluoride is
able to influence chemical exchanges between the tooth mineral
and the surrounding plaque fluid even at very low concentrations.
Emphasis was then made on topical fluoride treatments such as
fluoridated toothpastes. Today, fluoride is considered as a key pro-
tective factor which interacts directly on the tooth surface. The
posteruptive effect is now considered as major compared to the
pre-eruptive one (Featherstone 1999; Fejerskov 2004).
The pre-eruptive and posteruptive effects of fluoride are not easy
to separate when analysing results of clinical and epidemiological
studies. This is due to different factors. It is impossible to conduct
randomised controlled trials of fluoride supplementation or wa-
ter fluoridation to determine how much of the anti-caries effect
was obtained from pre- or posteruptive effect. Additionally, what
complicates this issue is that maximum protection against caries
is obtained when teeth erupt into an environment with low con-
centrations of fluoride in the mouth; and hence systemic or pre-
eruptive effects are not mutually exclusive phases. The context of
eruption is also an important factor; teeth emerging in a caries-
free mouth are at lower caries risk. There is a cumulative effect of
fluoride with an increased preventive effect for longer exposures
(Limeback 1999; Thylstrup 1990). Given all of these factors, it
is not possible in any one study to define clearly the posteruptive
effect of fluoride on dental caries.
Topically applied fluorides are not intended for ingestion and thus
act mainly posteruptively. Numerous clinical trials have investi-
gated the anti-caries effect of topical fluoride interventions and
several Cochrane systematic reviews have been conducted con-
firming the efficacy of topical fluorides as toothpastes, mouth
rinses, gels and varnish for preventing dental caries in children and
adolescents (Marinho 2002a; Marinho 2002b; Marinho 2003a;
Marinho 2003b). Concerning systemic intake of fluoride, it is dif-
ficult as stated above to ascertain whether there is a real pre-erup-
tive effect. Water fluoridation has been the principal approach for
community caries prevention. A systematic review reported that
water fluoridation is associated with an increased proportion of
children without caries and a reduction in the number of teeth
affected by caries. A dose-dependent increase in dental fluorosis
was also found (McDonagh 2000). In many countries, water flu-
oridation has not been implemented. Alternative sources of sys-
temic fluoride have thus been introduced, such as fluoridated salt
or fluoride supplements. Salt fluoridation is used in 30 countries
worldwide, mainly in Europe and in Central and South America.
A Cochrane systematic review evaluating the impact of salt fluo-
ridation in reducing caries levels and its potential harms is being
conducted (Gillespie 2007). Systematic reviews are available on
the effects of milk fluoridation (Yeung 2005) and salt fluoridation
(Yeung 2011). Some attempts have also beenmade to add fluoride
to sugar, bread and cereals.
Numerous clinical studies on the caries preventive effect of dietary
fluoride supplements are available. They have been conducted in
various countries in Western, Eastern and Northern Europe as
well as in North America (Strean 1946) as early as the 1940s
and recently in China. Earlier studies (before 1970 to 1980) were
conducted under ’ideal’ conditions as fluoridated toothpastes were
not widespread. They have been conducted in a period when it
was assumed that the cariostatic effect of fluoride was largely pre-
eruptive. Incorporation of fluoride in the forming enamel was seen
as essential and those studies were not intended to distinguish
between pre- and posteruptive effect. The early studies on fluoride
supplements were reviewed by Birch in 1969 (Birch 1969) and by
Binder et al in 1978 (Binder 1978). Later studies (after 1980) were
conducted in a context where many topical and systemic fluoride
sources co-existed. Children living in communities without water
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fluoridation might receive significant amounts of systemic fluoride
from foods and drinks processed in fluoridated communities, from
other sources of systemic fluoride such as fluoridated salt or from
involuntary ingestion of fluoride toothpastes. Those more recent
studies often focused on the posteruptive effect of fluoride. They
were conducted on schoolchildren whowere asked to chew or suck
the supplements before ingestion.
Later reviews published byRiordan (Riordan 1993; Riordan 1996;
Riordan 1999), Ismail (Ismail 1994; Ismail 2008) and Burt (Burt
1999) made a critical analysis of the literature to determine the
efficacy of fluoride supplements in caries prevention. Those re-
views stated that the evidence for efficacy of fluoride supplements
when used from birth was poor, that compliance with fluoride
supplement recommendations was low making them a poor pub-
lic health measure and that supplements use was a risk factor for
dental fluorosis (Ismail 1999). Since then, the place of fluoride
supplements in caries prevention has been re-evaluated in several
countries. Recommendations about their use have been modi-
fied. The age of initial use of supplements was delayed, the doses
recommended for different age groups were reduced and the use
of fluoride supplements was limited to high risk children (Adair
1999; Banting 1999). No meta-analysis has been conducted to
evaluate the efficacy of fluoride supplements. Recommendations
for the use of fluoride supplements vary around the world. The
caries preventive advice is often confusing to both dental public
health and private dental practitioners. This confusion explains
the fact that primary care physicians and paediatricians do not fol-
low completely the current fluoride supplementation guidelines
(Sohn 2007).
O B J E C T I V E S
(1) To evaluate the effects of fluoride supplements in the form of
tablets (chewable or not), drops, lozenges and chewing gums for
preventing dental caries in children.
(2) To examine whether the effects of fluoride supplements varies
according to the age of administration, background exposure to
topical fluoride and type of supplements used.
(3) To evaluate whether there is a differential effect between fluo-
ride supplements and topical fluorides.
(4) To evaluate whether there is a differential effect between fluo-
ride supplements and other caries preventive measures.
We considered fluoride supplements to include fluoride tablets
(chewable or not), drops, lozenges and chewing gums.
We excluded slow release devices, fluoridated toothpicks and gen-
erally nutritional fluoridation such as wheat, sugar, salt and water
fluoridation.
Fluoridated chewing gums are usually not considered as being
fluoride supplements. Nevertheless, we decided to include them
in this review for two reasons: firstly fluoride in chewing gums
is partly ingested; secondly chewable tablets and chewing gums
could be difficult to distinguish during the process of searching
for eligible studies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised (or quasi-randomised) controlled clinical
trials (RCTs) with randomisation at the level of the child or at the
level of a group (cluster).
We excluded other study designs such as non-randomised con-
trolled clinical trials, controlled before/after studies, prospective
cohort studies, single group before/after designs, historical control
studies, interrupted time series, observational and retrospective
epidemiological studies.
We excluded studies with an intervention or follow-up period of
less than 2 years.We considered that carious lesions preferably take
at least 2 years to develop or to be visible during a clinical exami-
nation, if the primary outcome is the number of newly developed
cavitated lesions (particularly when the D3MFT metric is used).
Types of participants
We included children or adolescents aged 16 or less at the start of
the study (irrespective of initial level of dental caries, background
exposure to fluorides, dental treatment level, nationality, setting
where intervention is received or time when it started).
We excluded older participants in order to avoid the selection of
studies concerning the use of fluoride supplements to prevent root
caries or to improve bone density.
We excluded studies including only participants aged 16 years and
older at baseline.
Types of interventions
Active intervention/test group
Fluoride supplements in the form of tablets, drops, lozenges (or
chewing gums):
• with or without the use of vitamins;
• using any fluoride agent, at any concentration, amount,
frequency of use, duration of application, and with any
technique of application (sucked or not, chewed or not);
• with or without the use of topical fluorides (fluoride rinse,
topical fluoride application, fluoride varnish or fluoride
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toothpaste) or non-fluoride based measures (chlorhexidine,
xylitol, sealants, oral hygiene interventions, etc).
Control group
No fluoride supplements:
• no treatment;
• use of a placebo supplement (with or without the use of
vitamins);
• use of topical fluorides (fluoride rinse, topical fluoride
application, fluoride varnish or fluoride toothpaste);
• use of other preventive measures (chlorhexidine, xylitol,
sealants, oral hygiene interventions, etc).
Other criteria
We excluded studies when the active intervention consisted of any
other systemically delivered fluoride (water, milk, salt) provided
in addition to fluoride supplements.
We excluded studies when a topical fluoride based measure or a
non-fluoride based preventive measure applied in a control group
was different from the one administered in the intervention group
in addition to fluoride supplements.
Types of outcome measures
Primary outcomes
For permanent and deciduous dentition, changes in caries incre-
ment, as measured by the difference between the number of de-
cayed, missing and filled teeth (dmft/DMFT) or surfaces (dmfs/
DMFS) at baseline and at the time of final evaluation for the same
children.
Secondary outcomes
For permanent and deciduous dentition:
1. Differences in final caries experience as measured by the
final number of decayed, missing and filled teeth (dmft/DMFT)
or surfaces (dmfs/DMFS) in the treatment and control groups (if
the groups were comparable at baseline).
2. Any other measures of dental caries such as proportion of
children developing new caries or changes in caries-free subjects.
3. Caries assessed clinically at the dentin level. If a combined
clinical and radiographic assessment had been used, we recorded
and noted this.
We excluded studies with no caries assessment and also studies
reporting only on changes in plaque/salivary bacterial counts, flu-
oride uptake by enamel or dentin or fluoride salivary secretion.
Adverse effects
We recorded adverse effects when reported (dental fluorosis when
assessed with a specific index and any other possible negative ef-
fects). A full investigation of adverse effects was not possible as we
excluded observational and retrospective epidemiological studies.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases:
• The Cochrane Oral Health Group’s Trials Register (to 12
October 2011) (see Appendix 5);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, Issue 3, 2011) (see
Appendix 4);
• MEDLINE via Ovid (1950 to 12 October 2011) (see
Appendix 1);
• EMBASE via Ovid (1974 to 12 October 2011) (see
Appendix 2);
• LILACS via BIREME Virtual Health Library (1982 to 12
October 2011) (see Appendix 3);
• PanAmerican via BIREME Virtual Health Library (1982 to
12 October 2011) (see Appendix 3);
• WHOLIS via BIREME Virtual Health Library (1982 to 12
October 2011)(see Appendix 3);
• MedCarib via BIREME Virtual Health Library (1982 to 12
October 2011) (see Appendix 3);
• Brazilian Bibliography of Dentistry (BBO) via BIREME
Virtual Health Library (1982 to 12 October 2011) (see
Appendix 3);
• Current Controlled Trials (www.controlled-trials.com/) (to
12 October 2011) (see Appendix 6).
We used a combination of controlled vocabulary and free text
terms for searching MEDLINE via Ovid (Appendix 1). We de-
cided not to use the Cochrane Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE, as published in
Box 6.4c in the Cochrane Handbook for Systematic Reviews of Inter-
ventions Version 5.1.0 (Higgins 2011), because many of the trials
eligible for this review were older and did not have an abstract,
and there was a risk of losing these potentially important studies.
We developed detailed search strategies for each database searched.
These were based on the search strategy developed for MEDLINE
but revised appropriately for each database to take account of
differences in controlled vocabulary and syntax rules (Appendix
2, Appendix 3, Appendix 4, Appendix 5, Appendix 6).
Searching other resources
We checked bibliographic references of identified trials and review
articles for additional studies.
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We contacted organisations and experts known to be involved
in the field when necessary to find unpublished studies. We sent
letters to authors of selected studies asking them for clarifications
and other known unpublished or ongoing research.
We identified journals in which trials in this field are likely to
be reported: Journal of Dental Research, Acta Odontologica Scandi-
navica, Journal of the American Dental Association, Swedish Dental
Journal, British Dental Journal, ASDC Journal of Dentistry for Chil-
dren, Archives of Oral Biology, Caries Research, Community Den-
tistry and Oral Epidemiology, Community Dental Health, Journal
of Public Health Dentistry. They have been handsearched as part
of The Cochrane Collaboration’s handsearching programme, thus
we did not need to handsearch them as part of the review process.
There was no restriction regarding language or date of publica-
tion or publication status. We were able to translate non-English
papers for languages such as French, German, Spanish and Rus-
sian. Cochrane Collaboration translators carried out translations
for any other languages.
Data collection and analysis
Selection of studies
We imported records resulting from the searching process into a
single database in the bibliographic software package Endnote.We
removed duplicates in order to facilitate the retrieval of relevant
articles.
Two review authors independently examined the title, keywords
and abstract of all reports identified by the search, taking into ac-
count inclusion and exclusion criteria. The review authors were
not blinded with respect to authors’ names, journal or date of
publication. If, in the opinion of both review authors, an article
clearly did not fulfil the defined inclusion criteria, we considered
it ineligible. For studies appearing to meet the inclusion criteria,
or for which there was insufficient data in the title and abstract to
make a clear decision, we obtained the full report. On receipt of
the full articles, the two review authors checked that each study
fulfilled the inclusion criteria. A third review author was consulted
to resolve any disagreement. Cochrane Collaboration translators
assessed trial reports in languages other thanFrench,German,Rus-
sian or Spanish for eligibility. When these studies were considered
eligible, a review author completed the inclusion form with the
help of the translator.
Data extraction and management
Two review authors extracted the data independently, using data
extraction forms. In case of discrepancy, we sought consensus. We
piloted the data extraction forms on 10 articles and made modifi-
cations where necessary. For each trial we recorded the following
data.
• Author(s), year of publication, number of reports on the
study, year/study began, country.
• Methods: study design, research objective, study duration,
method of allocation, randomisation/quasi-randomisation, unit
(individual/cluster), comparability of baseline characteristics,
blindness of participants, blindness in outcome assessment,
reliability of primary outcome measurement, co-intervention
and/or contamination, institutions and manufacturers involved,
local characteristics.
• Participants: setting where participants were recruited,
criteria for inclusion, demographic characteristics (age, gender,
socioeconomical status), caries severity, exposure to fluoride,
number at start and at the end of the study.
• Intervention: type of supplement used (tablet, lozenge,
drop, other), modalities of administration (chewing, etc),
treatment duration and application frequency, fluoride doses,
fluoride agents, combination of methods, compliance
(supervision of participants).
• Details of the outcomes: method of assessment (clinical/
radiographic, diagnostic thresholds used, account for reversals),
mean duration of study.
• Primary outcome measures (caries increment): units
measured (tooth/surface), index used (DMFT/S, DF/T, etc),
types of tooth/surface considered (deciduous, permanent), state
of tooth/surface eruption (erupted/erupting).
• Secondary outcome measures (variation of DMF index,
percentage of children with caries).
• Adverse effects (fluorosis) if recorded.
• Details of analysis: measures of effect, confidence intervals,
crude/adjusted results.
Disagreements between the two review authors were discussed and
a third review author was consulted when necessary. We contacted
the trial authors to find missing information. Studies rejected at
this stage were recorded in the ’Characteristics of excluded studies’
table. The ’Characteristics of included studies’ tables provide a
description of the data reported from each study.
Assessment of risk of bias in included studies
Two review authors independently carried out risk of bias assess-
ment following the domain-based evaluation described in Chap-
ter 8 of the Cochrane Handbook (Higgins 2011). The evalua-
tions were compared and any inconsistencies were discussed and
resolved. We contacted the study author(s) to seek clarification in
case of uncertainty over data.
In this two-part tool we assessed the following domains.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants, personnel and outcome assessors
(performance bias and detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
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• Other bias.
Each domain in the tool includes one or more specific entries in
a ’Risk of bias’ table. Within each entry, the first part of the tool
describes what was reported to have happened in the study, in
sufficient detail to support a judgement about the risk of bias. The
second part of the tool assigns a judgement relating to the risk of
bias for that entry. This is achieved by assigning a judgement of
’Low risk’ of bias, ’High risk’ of bias, or ’Unclear risk’ of bias.
After taking into account the additional information provided
by the authors of the trials, we graded studies into the following
categories.
• Low risk of bias: low risk of bias for all key domains.
• Unclear risk of bias: unclear risk of bias for one or more key
domains.
• High risk of bias: high risk of bias for one or more key
domains.
A risk of bias table was completed for each included study (see
’Characteristics of included studies’). Results are presented graph-
ically by study (Figure 1) and by domain over all studies (Figure
2).
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Measures of treatment effect
For the main outcome variable, we estimated the treatment effect
in each study by the prevented fraction (PF): mean caries incre-
ment in controlsminusmean caries increment in the treated group
divided by mean caries increment in controls. The PF is consid-
ered to be more appropriate than the standardised mean difference
(SMD) because it allows to combine different types of caries in-
crements data. We calculated the 95% confidence interval of the
PF using Stata following the formula of Dubey (Dubey 1965).We
calculated PFs by combining, when possible, several indexes. We
calculated the PF values separately for caries increment data at the
surface and tooth level and for deciduous and permanent teeth.
We conducted random-effects meta-analyses when data could be
pooled and we produced forest plot graphs. We used ReviewMan-
ager (RevMan 2011) and STATA software to conduct the statisti-
cal analysis.
Dealing with missing data
We calculated missing caries increment values when necessary.
Depending on the studies, we calculated caries increment either by
subtracting initial DMFS (or DMFT) to final DMFS (or DMFT)
or by adding caries increment for erupting teeth and for already
erupted teeth.
We imputedmissing standard deviations that were not obtained by
contacting the original researchers (Van Rijkom 1998). Expecting
increment to be approximately a Poisson variable, we supposed
the log of standard deviation to be a linear function of the log
of the mean. We estimated the parameters of the function by
means of a simple regression over all the studies included in the
analysis. We decided to estimate two separate regression lines for
the increments in surface and the increments in number of teeth
(there were actually no studies with missing standard deviation
for increment of teeth). We also estimated two separate regression
lines for the intervention and control groups. We did not separate
permanent and deciduous teeth.We included results of all follow-
ups.
Assessment of heterogeneity
We assessed heterogeneity in the studies’ results by examining for-
est plots and by using formal tests for homogeneity based on the
I² statistics.
Assessment of reporting biases
We explored publication biases by drawing funnel plots and by
investigating their degrees of asymmetry.
Data synthesis
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We calculated estimates of treatment effects (PFs) using the Stata
software package. We conducted meta-analyses with Revman (
RevMan 2011), using a random-effects model for the PF data.
We conducted four different types of comparisons.
1. We first estimated treatment effects for studies or study
groups comparing the administration of fluoride supplements
with no treatment or with a placebo.
2. Then, we estimated treatment effects for studies or study
groups comparing the administration of fluoride supplements
with the application of topical fluorides. Some studies were
considered in two different types of comparisons (1 and 2) when
they included several control groups with and without the use of
topical fluorides.
3. We examined studies which compared the effects of
fluoride supplements to other preventive measures separately.
4. We conducted a complementary comparison to explore
variations in PF values calculated for teeth already erupted at the
start, and teeth erupting during, the study period.
For each type of comparison, we estimated the combined effect
separately using different outcome categories for deciduous and
permanent teeth. We also considered caries increments calculated
at the tooth level and at the surface level separately. We calculated
PFs by combining several indexes as DS (decayed surfaces), DFS
(decayed and filled surfaces), and DMFS (decayed, missing and
filled surfaces). We considered some studies in two different sub-
groups when they included several types of outcome on perma-
nent or deciduous teeth, or at the tooth or surface levels.
We carried out main analyses for a length of follow-up of 24 to 36
months, which was the more frequent duration of the studies. We
performed complementary analyses for data in studies including
longer follow-ups. We estimated PFs separately for the different
lengths of follow-up extracted from the same studies.
In the studieswithmore thanone intervention group, such as those
comparing different frequencies of application or different types
of supplements, we considered the results (numbers, mean caries
increments and standard deviations) fromall relevant experimental
groups separately in the meta-analyses.
Subgroup analysis and investigation of heterogeneity
We assessed heterogeneity by inspection of forest plots of the esti-
mates and confidence intervals of treatment effects.
The following variables were taken into account to explore the
differences in PF values: type of control group (placebo, no treat-
ment), type of topical fluoride used in the control group if any
(fluoride toothpaste, varnish, mouthwash), children’s age at start,
type of supplements used (tablets, drops, lozenges, sodium flu-
oride (NaF), acidulated phosphate fluoride (APF), dosage), year
when the study began (which indicated background exposure to
fluoridated toothpastes) and (oral) health status of the children
(special needs children, children with high caries risk). We also
assessed the influence of some study characteristics such as ran-
domisation, blindness in caries assessment or percentage of drop
out when possible. Due to the small number of PF values, it was
not possible to create subgroups or to conduct a meta-regression
to formally explore the influence of those study characteristics.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
The results of the different electronic searches are presented in
Table 1. Following the removal of duplicates, 1416 records were
retrieved from the electronic database search. The search of non-
electronic resources retrieved 28 other potentially relevant records.
We screened records on the basis of the title, keywords and ab-
stract. We arranged the translation of non-English articles when
necessary and we used English abstracts, when available, to iden-
tify if they were eligible studies. The members of the review group
translated reports in French, Spanish, German and Russian. Per-
sonal contacts or members of the Cochrane Collaboration trans-
lated other reports.
After this initial screening, we considered 79 records to be poten-
tially eligible, and proceededwith amore detailed assessment. This
resulted in 11 included studies (23 reports + 3 postintervention
reports) and 38 excluded studies (49 reports). Two reports from
the PAHO database related to the evaluation of the Bermuda di-
etary supplement program could not be found and we added them
to the ’Studies awaiting classification’ section (Horowitz 1994).
We added one study with no information about the treatment ad-
ministered to the control group to the same section (Niedenthal
1957). We also added one Thai study for which the characteristics
and quality were difficult to evaluate to this section (Prasertsom
1992). We found few relevant reports relating to the use of fluo-
ride chewing gums (n = 3) and we excluded these.
Included studies
See ’Characteristics of included studies’ tables for details of in-
cluded studies.
We included 11 studies in the review, of which three have more
than one publication giving results for different follow-ups. Re-
ports were published between 1968 and 2008 and referred to stud-
ies conducted mainly in Sweden and USA, but also in UK, Den-
mark and Taiwan.
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Design and methods
The review includes placebo controlled trials but also trials com-
paring the treatment group to other active interventions or to
no treatment. In the control groups, placebo supplements were
administered in three studies (Aasenden 1972; DePaola 1968;
Driscoll 1974) and no treatment in two other studies (Lin 2000;
O’Rourke 1988). In one study (Källestål 2000), a letterwith tooth-
brushing instructions was sent to the parents of the children in
the control group; this group was not considered in the analysis
as a ’no treatment group’. In five studies, the effect of fluoride
supplements was compared with the use of topical fluoride: flu-
oride rinse (Heifetz 1987; Holm 1975; Poulsen 1981), fluoride
varnish (Källestål 2000; Petersson 1985) or fluoridated toothpaste
(Petersson 1985). In one study, the effect of xylitol and xylitol/flu-
oride-containing lozenges was compared (Stecksen-Blicks 2008).
The review includes trials with two to five arms. Three studies had
more than one treatment group in addition to a control group.
In those three studies, the effect of the sodium fluoride (NaF)
tablets was comparedwithNaF drops (Lin 2000), acidulated phos-
phate fluoride (APF) tablet once a day with APF tablets twice a
day (Driscoll 1974) and APF supplements with NaF supplements
(Aasenden 1972). Two studies used more than one control group.
In one of those studies the fluoride supplements were compared
with the application of fluoride varnish and use of fluoridated
toothpastes (Petersson 1985), while in the other study the prescrip-
tion of fluoride lozenges was compared with parental information,
fluoride varnish applications or individual prevention (Källestål
2000). In this latter study, comparisons other that the one made
between fluoride supplements and fluoride varnish applications
were not considered in the meta-analysis.
Studies were generally large with only two studies allocating less
than 100 children to relevant study groups (Lin 2000; Stecksen-
Blicks 2008). The total number of children participating in the
trials was 7196 (number of children at start), and ranged from 140
in the smallest trial (Lin 2000) to 1640 in the largest trial (Heifetz
1987), with an average of 654 participants per trial.
Participants
Participants were recruited from school settings in seven studies
and were patients of selected dental clinics in the four other studies
(Källestål 2000; Lin 2000; Petersson 1985; Stecksen-Blicks 2008).
The ages of the children at the start ranged from 2 to 12 years.
Two trials included children who were aged 2 to 3 years (Lin 2000;
Petersson 1985) and three included children aged 5 to 6 years
(Driscoll 1974; Heifetz 1987; O’Rourke 1988). The participants
of the five other studies were older, aged from 7 to 12 years.
In two studies, participants were children with high caries risk
(Källestål 2000; Stecksen-Blicks 2008), and in one study, partici-
pants were children with cleft lip and/or palate (Lin 2000).
Decayed, (missing) and filled surfaces (DMFS) data at baseline
were reported in eight studies and ranged from 0.24 DMFS
(Heifetz 1987) to 8.6 DFS (Aasenden 1972). Baseline data for de-
ciduous tooth surface (dmfs) were reported in three studies vary-
ing from 0.9 dfs to 4.73 dmfs (Heifetz 1987; Lin 2000; Petersson
1985).
Information on ’background exposure to other fluoride sources’
was not always available. All the studies were conducted in com-
munities with no water fluoridation (< 0.1 ppm) except in one
study (Källestål 2000) where parents answered a questionnaire and
indicated the fluoride content of the water they consumed. Gen-
eralised use of fluoridated toothpastes was reported in three stud-
ies (Heifetz 1987; Källestål 2000; Stecksen-Blicks 2008). In one
study, the use of topical fluoride was indicated: “many schools at
that time got fluoridemouthwash on aweekly basis” (Holm 1975).
In the study conducted in Taiwan in children aged 2 to 3 years (Lin
2000), the authors indicated that toothbrushing was done without
fluoridated toothpastes. The absence of exposure to fluoridated
toothpastes could be assumed based on year of publication (before
1975) for three studies (Aasenden 1972; DePaola 1968; Driscoll
1974). Nevertheless, in one study conducted in 1972 in the USA,
the authors stated that the majority of the children had a history
of some kind of topical fluoride exposure (Aasenden 1972). No
information was available concerning exposure to topical fluorides
in three trials conducted in Europe during the 1980s (O’Rourke
1988; Petersson 1985; Poulsen 1981). Thus some form of fluo-
ride exposure could be considered for five trials and no exposure
for one, with the information not available for the remaining five
trials.
Interventions
Four of the included trials (Källestål 2000; Lin 2000; Petersson
1985; Stecksen-Blicks 2008) reported unsupervised use of fluoride
supplements at home while in the remaining seven trials, supple-
ments were used under supervision at school. The compliance has
been evaluated in two of the four studies where supplements were
given at home (Källestål 2000; Stecksen-Blicks 2008).
Fluoride supplements were administered through different forms:
drops in one study (Lin 2000), tablets in seven studies (DePaola
1968; Driscoll 1974; Heifetz 1987; Holm 1975; Lin 2000;
O’Rourke 1988; Petersson 1985), tablets diluted in a solution in
one study (Aasenden 1972) and lozenges in three studies (Källestål
2000; Poulsen 1981; Stecksen-Blicks 2008).
Two types of fluoride agents were tested, including neutral sodium
fluoride (NaF) in 10 trials and acidulated phosphate fluoride (APF)
in three trials (Aasenden 1972; DePaola 1968; Driscoll 1974).
The fluoride dosages of the supplements ranged from 0.25mg to 1
mgof fluoride (F). The daily administration of 1mgFwas tested in
five trials (Aasenden1972;DePaola 1968;Heifetz 1987;O’Rourke
1988; Poulsen 1981). In one study, the administration of tablets
with 1 mg F once or twice a day was compared (Driscoll 1974).
Three studies investigated daily administration of supplements
with lower fluoride levels (0.4 to 0.5 mg F) (Holm 1975; Lin
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2000; Petersson 1985). In one of those studies (Petersson 1985),
tablets with 0.25 mg F were given twice a day. In two studies, one
to two lozenges with 0.25 mg F were administered three times a
day (Källestål 2000; Stecksen-Blicks 2008).
Outcome measures
Ten studies reported caries increment data at the surface level
which was the primary outcome measure. In one study, caries in-
crement was recorded at the tooth level only (O’Rourke 1988).
The majority of studies (n = 9) reported results for the permanent
dentition. Four trials gave data about caries increment for decid-
uous teeth: dmfs increment was reported in two studies (Heifetz
1987; Lin 2000), dfs in one study (Petersson 1985) and dmft in
two studies (Lin 2000; O’Rourke 1988). Two trials reporting ef-
fects on the deciduous dentition also assessed effects on perma-
nent teeth (Heifetz 1987; O’Rourke 1988). With regard to the
components of the DMFS index used, five trials reported DMFS
data (Driscoll 1974; Heifetz 1987; Källestål 2000; Poulsen 1981;
Stecksen-Blicks 2008), two reported DFS data (Aasenden 1972;
DePaola 1968), and one trial reportedDS data only (Holm 1975).
Results based on all tooth/surface types were reported in nine tri-
als. In one study, caries increment was available only for approxi-
mal surfaces (Stecksen-Blicks 2008). In two studies, caries incre-
ment was given separately for teeth erupting during the study and
teeth present at baseline (Poulsen 1981) or per age group (Poulsen
1981).
Two studies reported other dental caries data as the frequency dis-
tribution of new manifest carious surfaces and the distribution of
the children according to the number of erupted surfaces, group,
baseline DMFS and caries increment (Petersson 1985; Poulsen
1981). Caries increment has been reported for all teeth/surfaces
assessed but also according to the type of surface (occlusal, ap-
proximal, buccal/lingual) in three studies (Heifetz 1987; Holm
1975; Petersson 1985) and according to the status of eruption
(erupted at baseline versus erupting during the study) in four stud-
ies (Aasenden 1972; Driscoll 1974; Heifetz 1987; Poulsen 1981).
Diagnostic methods used were described in all studies, but thresh-
olds used for caries detection and monitoring of caries incidence
were not always clearly described. Three studies took into account
the reversals (DePaola 1968; Driscoll 1974; Källestål 2000). One
examiner made the dental examinations in four studies (Aasenden
1972; DePaola 1968; O’Rourke 1988; Poulsen 1981) while sev-
eral examiners conducted the evaluation in the other studies. Only
four studies reported some data about examiners’ reproducibil-
ity (Heifetz 1987; Källestål 2000; Lin 2000; Stecksen-Blicks
2008). Clinical examinations (Driscoll 1974; Heifetz 1987; Lin
2000; O’Rourke 1988) or clinical and radiographic examinations
(Aasenden 1972; DePaola 1968; Holm 1975; Källestål 2000;
Petersson 1985; Poulsen 1981; Stecksen-Blicks 2008) were con-
ducted to determine dental status and calculate caries increment.
Some studies reported other data: carious risk factors (Källestål
2000), costs (Källestål 2000; O’Rourke 1988), number of chil-
dren experiencing pain, anaesthesia and fear (O’Rourke 1988) and
oral hygiene status (Holm 1975). Enamel biopsies were made on
children from one study (Aasenden 1972). In two trials (Driscoll
1974; Heifetz 1987), assessments of DMFS increments or adverse
effects (fluorosis) were made during a postintervention follow-up
period (Driscoll 1979; Driscoll 1981; Nowjack-Raymer 1995).
Adverse effects were unreported in the majority of studies. Data
on fluorosis were reported in one study (Driscoll 1974).
Follow-ups of 24 to 36 months were the most common (reported
in all 11 trials). Three trials presented alsoDMFS/Tdata for longer
follow-ups (Driscoll 1974; Heifetz 1987; Källestål 2000). Analysis
was undertaken on results nearest to 24 to 36 months follow-up.
We conducted complementary analysis for longer follow-ups.
Excluded studies
Reasons for exclusion of the studies are given in the ’Characteristics
of excluded studies’ table. The 38 studies (49 reports) in this sec-
tion were excluded for a variety of reasons: non-random alloca-
tion; randomisation not stated or indicated; administration of ad-
ditional preventive agents; insufficient length of follow-up; lack of
longitudinal follow-up; fluoride agent which did not fulfil the def-
inition of fluoride supplements; lack of data (no values for caries
indexes). A trial could be excluded for more than one reason.
Risk of bias in included studies
The results of the assessment of the risk of bias in included studies
are summarised in Figure 1 and Figure 2.
Many aspects of the quality of the studies were unclear as insuf-
ficient information was available in the reports. The assessment
of blinding and absence of selective reporting was easier as more
information was given in the manuscripts.
Only one study (Stecksen-Blicks 2008) had three domains of the
risk of bias assessment (allocation concealment, blinding, free of
selective reporting) rated as being at low risk of bias. Four studies
were rated as having a low risk of bias for blinding and absence
of selective reporting (Aasenden 1972; Heifetz 1987; Lin 2000;
Poulsen 1981). Other studies had only one domain rated as being
at low risk of bias.
Overall, we rated 10 trials as being at unclear risk of bias and one
at high risk of bias (Källestål 2000).
Allocation
Random sequence generation
None of the included studies clearly reported the randomisation
process. In nine trials, statements such as “were randomised” or
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“randomly assigned” appeared but there was no description of the
process of randomisation.
In one study (Holm 1975), children were not allocated individ-
ually to the study groups. School classes were randomly divided
into the two study groups.
In another study (Petersson 1985), sequence generation was not
described as being randomised but we judged it as being quasi-
randomised because it was stated that: “children were listed in
official population list and numbered I to IV consecutively and in
this way 4 groups were formed”.
Allocation concealment
In all the studies except one (Stecksen-Blicks 2008), there was no
information about the way the generated randomisation sequence
was concealed from individuals involved in the enrolment and as-
signment of participants. We therefore considered allocation con-
cealment to be at low risk of bias for one study (Stecksen-Blicks
2008) and unclear risk of bias for the remaining 10 studies.
Blinding
Double-blinding with blind outcome assessment and use of a
placebowas described infive trials (Aasenden 1972;DePaola 1968;
Driscoll 1974; Poulsen 1981; Stecksen-Blicks 2008). In two of
those trials (DePaola 1968; Driscoll 1974), the product used as
control was not identical to the test product as colour coded bottles
were used. Hence blinding of participants and examiners could
have been compromised and we rated these studies as ’unclear’ for
this domain.
Single-blinding (blind dental caries assessment) with no placebo
use was described in four trials (Heifetz 1987; Holm 1975; Lin
2000; O’Rourke 1988).
In one trial (Petersson 1985), blind outcome assessment was un-
clear as “examiners were not aware to which group the child be-
longed but clinical examinations were made by two dentists who
also introduced the prophylactic programs and conducted neces-
sary restorative treatments”.
In another study (Källestål 2000), blind outcome assessment was
not achieved as it is stated that: “The collaboration with the clini-
cians and their crucial contribution to the data collection made it
impossible to do the caries registration in a blinded fashion.”
Incomplete outcome data
Participants included in the final analysis (24 to 36months follow-
up) as a proportion of the participants present at the start in all
studieswas 72.4%(5210 analysed out of 7196 randomised). There
was considerable variation in drop-out rates ranging from 5%
(Petersson 1985) to 29.6% at 2 years (Heifetz 1987). A common
reason for attrition was that participants were not available for
follow-up examination at the end of the study. Authors frequently
stated that children moved from the area or the school for reasons
unrelated to the study. The number of children lost or excluded,
by reason for attrition or by study group, was not reported. There
was therefore not enough information to determine the level of
risk of bias (high or low). We judged 10 studies as being at unclear
risk of bias for this domain due to a lack of information about
attrition rates by group. We evaluated one study (Petersson 1985),
with a very low drop-out rate of 5% after 2 years, as having a low
risk of bias for this domain.
Selective reporting
We considered selective reporting to be at low risk of bias for
seven trials as data on caries increment were reported in the results
section in accordance with the prespecified indexes announced in
the methods section.
In four studies (Holm 1975; Källestål 2000; O’Rourke 1988;
Petersson 1985), methods for the evaluation of outcomes were
insufficiently described and caries increment data were scarce, so
these studies were judged as being at unclear risk of bias for this
domain.
Other potential sources of bias
Baseline characteristics
In almost all the trials, it was stated that study groups were com-
parable at baseline for the initial caries levels. Slight differences
indicating some degree of imbalance were noted in only one trial
(Driscoll 1974).
Free of contamination or co-intervention
All the studies were judged free from the possibility of the ad-
ministration of the intervention to children in the control group
(contamination) or of the application of an additional treatment
to one of the groups (co-intervention). They were judged to be at
low risk of bias for this.
Reliability and validity of caries assessment
Only one study (Källestål 2000) presented data on the reliability
and validity of caries assessments. Also, reversals were not adjusted
for in the calculation of increments in all the studies. Overall, there
may be significant inconsistencies in how the outcome measures
were measured and analysed.
Effects of interventions
See: Summary of findings for the main comparison Fluoride
supplements compared to no fluoride supplement for preventing
dental caries; Summary of findings 2 Fluoride supplements
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compared to topical fluoride for preventing dental caries;
Summary of findings 3 Fluoride supplements compared to other
preventive measures for preventing dental caries
Effect of fluoride supplements on dental caries
increment
We have reported the results separately for permanent and decid-
uous teeth. We calculated the prevented fractions (PFs) separately
for decayed, missing and filled surfaces (DMFS) and for decayed,
missing and filled teeth (DMFT).We calculated PFs by combining
when possible several indexes such as DMFS and DFS (D(M)FS),
DMFS, DFS and DS (D(MF)S), DMFT and DFT (D(M)FT).
Data issued from follow-ups ranging from 24 to 36 months were
grouped and this length was the reference period used for all the
analyses. We calculated PF values separately for longer lengths of
follow-up.
In two studies, some caries increment data were not available. In
one study (Källestål 2000), caries increment was calculated by sub-
tracting initial DMFS or DMFT to final DMFS or DMFT for
follow-ups other than 48 months. In one study (Poulsen 1981),
caries increment was calculated by adding caries increment for
teeth erupting during the study and caries increment for teeth
erupted at start. Standard deviations (SDs) of mean caries incre-
ments were missing in one study (Petersson 1985). We calculated
missing standard deviations using a linear regression (Table 2).
(1) Effect of fluoride supplements when compared with no
fluoride supplement
(1-1) Effect on permanent tooth surfaces: D(M)FS PFs for a
follow-up of 24 to 36 months (Figure 3)
(see Figure 3)
Figure 3. Forest plot of comparison: 1 Fluoride supplements vs no fluoride supplement - outcome: 1.1
D(M)FS (24-36 months) PFs
TheD(M)FS PF pooled estimate was 0.24 (95% confidence inter-
val (CI) 0.16 to 0.33) suggesting a benefit from the use of fluoride
supplements (P < 0.00001). No heterogeneity was observed. We
extracted data from three studies conducted in the period 1968 to
1974 which included schoolchildren aged from 6 to 11 years at
baseline. In those three studies, the effect of NaF or APF tablets
(1 mg F), used once or twice a day and diluted or chewed was
compared to placebo tablets through five treatment groups.
(1-2) (1-3) Effect on permanent tooth surfaces: DMFS PFs
for longer follow-ups (55 and 72 months)
Results for other follow-ups were available from one study
(Driscoll 1974). The DMFS PFs varied from 0.25 (95% CI 0.12
to 0.38) after 55 months of follow-up to 0.28 (95% CI 0.16 to
0.41) after 72 months, indicating a benefit from the use of flu-
oride supplements (P < 0.0001). This study began in 1969 and
concerned children aged 6 years, and evaluated the effect of APF
tablets (1 mg F) administered once or twice a day.
(1-4) Effect on permanent teeth: D(M)FT PFs for a follow-
up of 24 to 36 months
For three trials combined, the D(M)FT PF pooled estimate was
0.29 (95% CI 0.19 to 0.39) suggesting a substantial benefit from
the use of fluoride supplements (P < 0.00001). No heterogeneity
was observed. We extracted data from studies conducted in the
period 1968 to 1988 which included children aged from 5 to
11 years at baseline (Aasenden 1972; DePaola 1968; O’Rourke
1988). The effect of APF and NaF tablets (1 mg F), diluted or
not, used once a day at school was compared with placebo tablets
or no treatment.
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(1-5) (1-6) Effect on deciduous tooth surfaces: dmfs PFs and
dmft PFs for a follow-up of 24 to 36 months
Heterogeneity was important when pooling the dmft PF values of
two studies (Chi² = 14.54 (df = 2); P < 0.0007).
No significant effect was found for one study with a dmft PF of
0.13 (95% CI -0.09 to 0.35) (O’Rourke 1988). Children were 5
years of age at the start and the administration of fluoride tablets
(1 mg F) at school was compared with no treatment.
A strong beneficial effect was observed in the other study which
included children with cleft lip and/or palate for dmft PF (0.65;
95% CI 0.47 to 0.84) (P < 0.00001) and for dmfs PF (0.73; 95%
CI 0.46 to 0.99) (P < 0.00001). The number of children studied
was small in this study (n = 115). Children were aged 22 to 26
months at the start and two types of fluoride supplements (tablets
and drops, 0.5 mg F) were tested versus no treatment. Children
did not use topical fluoride in all the study groups.
(2) Effect of fluoride supplements when compared with
topical fluoride (fluoride rinse, fluoride varnish, fluoridated
toothpastes)
(2-1) Effect on permanent tooth surfaces: D(MF)S PFs for a
follow-up of 24 to 36 months (Figure 4)
(see Figure 4)
Figure 4. Forest plot of comparison: 2 Fluoride supplements vs topical fluoride - outcome: 2.1 D(MF)S (24-
36 months) PFs
Four trials were combined (Heifetz 1987; Holm 1975; Källestål
2000; Poulsen 1981). The D(MF)S PF pooled estimate was -
0.10 (95% CI -0.25 to 0.05) suggesting no benefit from the use
of fluoride supplements when compared with the use of topical
fluoride. No heterogeneity in the results was observed. In these
studies, the fluoride supplements (tablets or lozenges) the children’s
ages (5 to 12 years), the study periods (1975 to 2000) and the
topical fluorides used (rinses or varnishes) were different but this
did not seem to influence the D(MF)S PFs.
(2-2) (2-3) (2-4) Effect on permanent tooth surfaces: DMFS
PFs for longer follow-ups (48, 60 and 96 months)
Results for other follow-ups were available from two studies
(Heifetz 1987; Källestål 2000). No effect from the use of fluo-
ride supplements when compared with the use of topical fluoride
was observed after 48 or 60 months of follow-up. There was het-
erogeneity between the two studies for the 60 months follow-up
(Chi² = 3.01 (df = 1); P = 0.08; I² = 67%). A beneficial effect of
fluoride supplements was noticed with a DMFS PF of 0.21 (95%
CI 0.04 to 0.38) (P = 0.02) for the longer follow-up (96 months).
It must be noted that a very high level of drop outs (> 60%) was
observed in this study for this length of follow-up (Heifetz 1987).
(2-5) Effect on deciduous tooth surfaces: d(m)fs PFs for a
follow-up of 24 to 36 months (Figure 5)
(see Figure 5)
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Figure 5. Forest plot of comparison: 2 Fluoride supplements vs topical fluoride, outcome 2.5 d(m)fs (24-36
months) PFs
No significant effect or heterogeneity was observed in this anal-
ysis which concerned two studies (four groups) (Heifetz 1987;
Petersson 1985). For all trials combined, the d(m)fs PF pooled
estimate was 0.13 (95% CI -0.07 to 0.33). In these studies, the
children’s ages (3 and 6 years) and the topical fluorides used (var-
nishes, toothpastes, rinses) were different but this did not seem to
influence the d(m)fs PFs.
(3) Effect of fluoride supplements when compared with
other preventive measures
(3-1) Effect on permanent tooth surfaces: DMFS approximal
PFs for a follow-up of 24 to 36 months
No significant effectwas observed in this analysis which concerned
only one study (Stecksen-Blicks 2008). For this trial, the DMFS
approximal PF was 0.00 (95% CI -0.59 to 0.59) when fluoride
given in addition to xylitol in lozenges was compared with xylitol
alone. This 2-year study started in 2001 and concerned children
aged 10 to 12 years at the start.
(4) Subgroup analysis and investigation of heterogeneity
We were not able to conduct a meta-regression due to the small
number of studies available for each outcome and for a length of
follow-up of 24 to 36 months (9 PF values for dmfs/d(m)ft, 2 PF
values for D(M)FT and 11 PF values for D(MF)S).
Due to the small number of studies, it was not possible to examine
the effects of some study characteristics such as randomisation,
blindness in caries assessment or percentage of drop out.
Due to the small number of studies, it was not possible to examine
the effects of fluoride supplements according to the types of sup-
plements, age of the children or background exposure to topical
fluorides.
The influence of some explanatory variables on caries increments
by study group was explored in two studies. In one trial, the num-
ber of erupted teeth, age and baseline DMFS were taken into ac-
count. The effect of fluoride supplements was higher for children
with caries at baseline in the younger age group (Poulsen 1981).
In another study (Källestål 2000), a multidimensional analysis
was conducted and the variables socioeconomic status, ethnicity,
earlier preventive program, sealants, self-administration of fluo-
ride, eating sweets and toothbrushing frequency significantly in-
fluenced caries increment in addition to the study group. In this
multidimensional analysis, no significant effect was found for the
group with fluoride supplements when compared with the refer-
ence group (with toothbrushing information).
(5) Funnel plot and test for funnel plot asymmetry: D(M)FS
PF
Due to the small number of studies, it was not possible to assess
publication bias except for analysis (1-1) Effect on permanent
tooth surfaces D(M)FS (24 to 36 months) PFs (Figure 6) and
analysis (2-1) Effect on permanent tooth surfaces D(MF)S (24 to
36 months) PFs (Figure 7). No publication bias was apparent but
these results must be considered with caution as the number of
studies was very small.
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Figure 6. Funnel plot of comparison: Fluoride supplements vs no fluoride supplement - outcome D(M)FS
(24-36 months) PFs
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Figure 7. Funnel plot of comparison: Fluoride supplements vs topical Fluoride - outcome: D(MF)S (24-36
months) PFs
Effect of fluoride supplements on other outcomes
We did not conduct a meta-analysis for secondary outcomes be-
cause data were scarce and non-homogenous.
Caries increments per type of surfaces (occlusal, bucco-lingual,
mesio-distal) were given in three studies. No difference in caries
increments per type of surface was observed in two studies (Holm
1975; Petersson 1985). In another study, the effect of fluoride
supplements (when compared to fluoride rinse) was higher for
occlusal surfaces (Heifetz 1987).
In one study, the effect of fluoride supplements on plaque and gin-
givitis was evaluated. There was no difference between the groups
(fluoride supplements versus fluoride rinses) for the mean plaque
and gingivitis scores after 2 years (Holm 1975).
Costs were studied in two trials. In one study, no cost-effectiveness
analysis was conducted for the group with fluoride supplements
because there was no significant effect when compared to the ref-
erence group (with toothbrushing information) (Källestål 2000).
In another study, a reduction of 19% in the cost of treatments
(for both dentitions) was found for the group with fluoride sup-
plements when compared to a control group. In the group with
fluoride supplements, there was a lower number of children un-
dergoing general anaesthesia after 2 years (O’Rourke 1988).
A complementary descriptive analysis was conducted to assess the
effect of fluoride supplements applied posteruptively and pre- and
posteruptively. Caries increments given for “teeth already erupted
at the beginning of the study” evaluated the posteruptive effect of
fluoride supplements. Caries increments given for “teeth erupting
during the study” evaluated the pre- and posteruptive effect of flu-
oride supplements. Data were available from two studies where the
effects of fluoride supplements have been compared to placebos
(Aasenden 1972; Driscoll 1974). These studies were conducted
among children aged 6 to 11 years at baseline and followed during
2 to 6 years. The total and subtotals D(M)FS PF pooled estimates
were not calculated because data were obtained for different fol-
low-ups of the same studies. Results indicate that the PF values
tended to be higher for teeth erupting lately than for teeth already
erupted at the beginning of the study period. For teeth erupted at
start, the PF values varied from a minimum of -0.06 (95% CI -
0.16 to 0.28) to a maximum of 0.27 (95% CI 0.13 to 0.41) ac-
cording to the length of follow-up, the type and the frequency of
use of fluoride supplements. For teeth erupting lately during the
study period, the PF values varied from a minimum of 0.27 (95%
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CI 0.13 to 0.41) to a maximum of 0.50 (95% CI 0.22 to 0.78).
In one study (Driscoll 1974), data were given concerning the dis-
tribution of children according to Dean’s fluorosis classification
after 55 months of study. Fluorosis was recorded on teeth that
erupted lately during the study period. For all study groups, 18.9%
of the children showed signs of dental fluorosis (questionable to
severe). The percentages varied slightly from 15% in the placebo
control group, 20% in the group with one APF tablet per day and
22% in the group with two APF tablets per day.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Fluoride supplements compared to topical fluoride for preventing dental caries
Patient or population: Children and adolescents
Settings: Supplements administered at school or at home in Sweden, North America and Danemark
Intervention: Fluoride supplements
Comparison: Topical Fluoride
Outcomes Illustrative comparative risks Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk1,2 Corresponding risk1,2
Topical fluoride Fluoride supplements
Caries increment on per-
manent tooth surfaces
(D(MF)S increment)
Follow-up: 24-36 months
The mean caries incre-
ment on permanent tooth
surfaces ranged across
control groups from
0.9 to 5.4 surfaces
The mean caries incre-
ment on permanent tooth
surfaces in the interven-
tion groups ranged from
0.8 to 6.1 surfaces
-0.10 [-0.25, 0.05] 2047
(5 studies)
⊕⊕⊕©
moderate
Random sequence gener-
ation, allocation conceal-
ment rated as unclear in
those 5 studies3
Caries increment on de-
ciduous tooth surfaces
(d(m)fs increment)
Follow-up: 24-36 months
The mean caries incre-
ment on deciduous tooth
surfaces in the control
group ranged from 1.7 to
2.5 surfaces
The mean caries incre-
ment on deciduous tooth
surfaces in the interven-
tion groups ranged from
1.8 to 2.06 surfaces
0.13 [-0.07, 0.33] 1051
(2 studies)
⊕⊕⊕©
moderate
Random sequence gener-
ation, allocation conceal-
ment rated as unclear in
those 2 studies3
Fluorosis (adverse ef-
fect)
% of children with fluo-
rotic teeth
See comment See comment Not estimable See comment See comment Not estimated
*The basis for the assumed risk (mean caries increment values in control groups) and corresponding risk (mean caries increment values in intervention groups) is provided in footnotes
The relative effect (95% confidence interval) is evaluated by calculating the prevented fraction = mean caries increment in controls minus mean caries increment in the treated group divided
by mean caries increment in controls.
CI: Confidence interval
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 DMFS/T: Number of tooth surfaces (S) or number or teeth (T) decayed, missing or filled due to dental caries
2 caries increment = final DMFS/T minus baseline DMFS/T
3 Many studies have been excluded from the review due to a lack of information concerning the allocation process
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Fluoride supplements compared to other preventive measures for preventing dental caries
Patient or population: Patients with preventing dental caries
Settings: Children and adolescents
Intervention: Fluoride supplements
Comparison: Other preventive measures
Outcomes Illustrative comparative risks* Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk1,2 Corresponding risk1,2
Other preventive mea-
sures
Fluoride supplements
Caries increment on per-
manent tooth surfaces
(DMFS increment on
proximal surfaces)
Follow-up: 24-36 months
The mean caries incre-
ment on permanent tooth
surfaces in the control
group was 2.7 surfaces
The mean caries incre-
ment on permanent tooth
surfaces in the interven-
tion group was 2.7 sur-
faces
0.00 [-0.59, 0.59] 115
(1 study)
⊕⊕©©
low
One study3, small sam-
ple, large confidence in-
terval. Caries increment
measured only on ap-
proximal surface
*The basis for the assumed risk (mean caries increment values in control groups) and corresponding risk (mean caries increment values in intervention groups) is provided in footnotes
The relative effect (95% confidence interval) is evaluated by calculating the prevented fraction = mean caries increment in controls minus mean caries increment in the treated group divided
by mean caries increment in controls.
CI: Confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 DMFS/T: Number of tooth surfaces (S) or number or teeth (T) decayed, missing or filled due to dental caries
2 caries increment = final DMFS/T minus baseline DMFS/T
3 Many studies have been excluded from the review due to a lack of information concerning the allocation process
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D I S C U S S I O N
Summary of main results
The main question addressed by this review was the efficacy of
fluoride supplements in the form of tablets, drops, lozenges or
chewing gums for preventing dental caries in children. A total of
7196 children (aged 2 to 12 years) participated in the 11 included
trials. In those studies, fluoride supplements were administered in
various forms (tablets, lozenges, drops) using two types of fluoride
agents: acidulated phosphate fluoride (APF) and sodium fluoride
(NaF). On the permanent dentition, the pooled results from the
three trials assessing the effect of fluoride supplements suggested
that the use of this intervention was associated with a 24% (95%
confidence interval 16% to 33%) reduction on average in decayed,
missing and filled tooth surfaces (D(M)FS) when compared with
no fluoride supplement. On deciduous teeth, one study was un-
clear about the evidence that fluoride supplements have a caries-
inhibiting effect when compared with no fluoride supplement. In
another study, the use of fluoride supplements was associated on
average with a 65% reduction in decayed, missing and filled teeth
(dmft) with a 95% confidence interval of 47% to 84%. There was
therefore only weak evidence that the use of fluoride supplements
prevents dental caries in deciduous teeth. When fluoride supple-
ments were compared with the use of topical fluorides in six trials
(varnish, rinses, toothpastes) or with the use of other preventive
measures in one trial (Xylitol lozenges), therewas no clear evidence
of a differential effect on permanent dentition nor on deciduous
teeth whatever the studies’ characteristics.
A secondary aim of this review was to examine whether there was
any relationship between the caries-preventive effect of fluoride
supplements and the age of administration, initial level of caries
severity, background exposure to topical fluorides or type of sup-
plements used. The influence of the type of supplements could
not be explored due to the large variation in types of supplements,
fluoride dosages, fluoride agents and methods of administration
used in the 11 included studies. Due to the small number of stud-
ies, we were not able to study the relationship between the age
of administration, the initial level of caries severity, background
exposure to topical fluorides and the magnitude of the treatment
effect.
Overall completeness and applicability of
evidence
We aimed to identify randomised controlled trials evaluating the
use of fluoride supplements in the prevention of caries.
The fewer trials in the deciduous dentition compared to themixed
or permanent dentition is of particular concern. This review in-
cluded mainly studies conducted among older children (> 6 years)
and which have studied the efficacy of fluoride supplements on
permanent teeth. A small number of studies concerned children
under the age of 5 to 6 years. We also found that there is little
evidence about the efficacy of fluoride supplements on deciduous
teeth when administered to very young children. No data were
available concerning adverse effects related to fluoride supplemen-
tation in children aged less than 6 years. The ratio benefit /risk of
fluoride supplementation was thus unknown for young children.
Moreover, we could not explore the effect of different dosages of
fluoride supplementation. We were unable to obtain valuable in-
formation about the effectiveness of fluoride supplements for in-
fants and preschool children.
This review provides little information about the risk of adverse
effects. Only one of the trials reported data about risk of fluorosis
where a slight increase in fluorosis prevalence was observed with
an increase in fluoride interventions in the study groups. No infor-
mation was reported on other adverse effects. The lack of data on
enamel fluorosis makes it difficult to evaluate the effectiveness of
fluoride supplements (the benefits of fluoride supplements use in
preventing caries against potential negative effects). This situation
can be explained by the type of studies considered (clinical trials),
the age of the participants at baseline in seven trials (7 to 12 years),
and a short length of follow-up for many trials (2 to 3 years). A
report (not included in the review) gives data about the prevalence
and severity of dental fluorosis in children who participated in
one of the clinical trials included in this review (Nowjack-Raymer
1995). Fluorosis was evaluated 3 years after the discontinuation
of the program on 448 (out of 1640) remaining children. Overall,
the prevalence of fluorosis was 4.4%. No statistically significant
differences existed in the prevalence or severity of fluorosis among
the preventive regimens, among children who began the regimens
at ages 5, 6, or 7 or by eruptive status of teeth.
For a long time, and especially in the USA, systemic fluorides have
been claimed to have pre- and posteruptive effects on dental caries.
This position is not widely shared as it is now widely considered
that the primary mode of action of fluoride is through topical
mechanisms when the fluoride ion is in the biofilm or is deposited
on the outer surface of enamel. Recent recommendations or re-
views have emphasised the importance of the posteruptive effect
of fluorides and encouraged that fluoride supplements should be
kept as long as possible in the mouth before swallowing (CDC
2001). In this review, it has not been possible to clearly distinguish
the pre-eruptive and posteruptive effect of fluoride supplements.
Many of the studies included in the review have evaluated the
posteruptive effect of fluoride supplements on older children (> 6
years) and on teeth that had already erupted in the oral cavity and
terminated the process of enamel mineralisation. In some stud-
ies, caries increments were calculated separately for teeth already
erupted at baseline and teeth erupting during the study. We found
that PF values tended to be higher for teeth erupting lately than
for teeth already erupted at the beginning of the study period.
Nevertheless, this trend did not allow any definitive conclusion
concerning a pre- or posteruptive effect of fluoride supplements.
The review does not address cost-effectiveness in terms of the po-
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tential reduction in financial cost associated with caries preven-
tion. We found some cost data in several included studies but it
was not possible to address cost-effectiveness in the review.
In one study, children in both groups (intervention and control)
received an additional non-fluoride agent (xylitol) which is known
to have an anticaries effect. The addition of xylitol in supplements
resulted in an additional preventive benefit. The influence of flu-
oride could have thus been difficult to highlight in this study.
All the included studies were conducted in communities with
no water fluoridation. Exposure to topical fluoride was identified
when possible but this information was not always available. Ex-
posure to topical fluoride, mainly from toothpastes, was thus esti-
mated by considering the year of the study. In several recent stud-
ies, the exposure to topical fluorides was clearly stated. The ab-
sence of exposure was assumed for studies conducted before 1975.
Thus, in some trials conducted during the 1980s, it was not pos-
sible to determine the level of exposure to fluoridated toothpastes.
This could be identified as a limitation of the review, nevertheless
this has not impacted greatly on the results of the analyses.
Fluoride supplements are considered as being as systemic source
of fluoride along with population level fluoride interventions such
as water, salt and milk fluoridation. Fluoride supplements differ
from other systemic sources as they are often prescribed at the
level of the individual and are dependant on patient compliance
for their effect. In this sense they fit more naturally with topical
fluorides such as toothpaste or mouthrinse. Compliance is a key
element which may influence the efficacy of fluoride supplements.
In the studies included in this review, the fluoride supplements
were distributed mainly in schools. Thus, the ability of families to
administer fluoride supplements to their child on a regular basis
could not be assessed. The compliance with fluoride supplements
administered at homewas assessed in only two studies. In these two
studies, different criteria were used to assess compliance. Forty-
one to 62% of the children were considered as having a good
compliance.
Quality of the evidence
The publication date of the studies included in this review vary
from 1968 to 2008. The quality of conduct and reporting of clin-
ical studies has improved during this time. This is clearly apparent
in the review given that a lot of information was lacking in earlier
studies.
Included studies and particularly older ones lacked information
on the methods of randomisation and on the process of allocation
concealment. They were thus considered as ’unclear’ for these
domains.
Blinding of participants was done in a few trials. In trials where
the effect of fluoride supplements was compared with topical fluo-
rides, double blinding was not possible. In some trials, blinding of
participants was stated but products were not similarly packaged.
The lack of blinding for participants has probably had minimal
consequences on outcome assessment.
The outcome assessment was carried out by examiners blinded
to treatment allocation in the majority of the included studies.
Nevertheless, blindness in outcome assessment could have been
compromised in two studies.
The primary outcome measure used in the included studies was
caries increment. Almost all studies have reported the caries in-
crement at a surface level but caries indexes used varied across the
studies. Some studies used global DMFS data but others reported
data with partial indexes such as DFS, DS, DMFS for approximal
surfaces, DMFS for teeth erupting or yet erupted at baseline. The
calculation of PF values allowed us to pool together those various
indexes.
Inmany studies, the reliability and validity of caries assessment was
not ensured. The reproducibility of caries assessment was not veri-
fied and diagnostic thresholds for caries detection were not clearly
defined. Errors or imprecise evaluations might have occurred dur-
ing caries assessments leading to a high risk of bias.
Risk of bias arising from imbalance of baseline caries levels across
groups was low. Stratification according to initial caries level was
employed in some trials. Moreover, the study groups were compa-
rable at baseline for the initial caries levels in the majority of the
included studies.
We included studies with a follow-up period of at least 2 years. A
follow-up period of 2 to 3 years is considered as optimal for studies
which report caries increment data at the dentinal level. This was
the case in this review because many studies were old and did not
report data at the enamel level. In studies with several follow-ups,
caries increment reported closest to this time (24 to 36 months)
was chosen as the outcome measure for this review.
The proportion of drop out after a 2 to 3 years period was not
negligible in the included studies. A common reason for attrition
was that participants were not available for follow-up examination
at the end of the study. Authors frequently stated that children
moved from the area or the school for reasons unrelated to the
study. The number of children lost or excluded by study group
and by reason for attrition was not reported. The risk of bias of
this domain was therefore unclear for the majority of studies.
A potential source of bias in the reviewwas the contamination from
other sources of fluoride or co-intervention. For studies which
took place in school settings, the risk of contamination was low
because the administration of fluoride supplements was carefully
supervised. A possible source of contamination was the use of
fluoride supplements in the control group and this might have
happened in studies where supplements were prescribed for home
use.
The risk of bias of the included studies was difficult to evaluate
and we frequently assessed the various domains as being at unclear
risk of bias. The studies included can not be considered to be free
from bias particularly for randomisation, allocation concealment
and quality of caries assessment.
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Potential biases in the review process
The results of this review help understand the effect of fluoride
supplements in the prevention of dental caries in children. Nev-
ertheless, there are several limitations that must be addressed.
The results of a meta-analysis depend on the studies included. We
have conducted a thorough search for studies but it is possible that
we did not locate all relevant studies, particularly those that were
unpublished. Studieswith positive results favouring treatmentmay
be more likely to be published; this could introduce bias into the
results.
Given that we chose to include only randomised or quasi-ran-
domised controlled trials (RCTsor quasi-RCTs), we excluded stud-
ies that used less stringent designs. The Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011) recommends to
consider as randomised studies, reports in which the word ’ran-
domised’ is clearly written. In older studies, the process of ran-
domisation was not clearly described. We excluded several studies
from this review because of a lack of information about the process
of randomisation. In several studies, the word ’randomisation’ was
not used and the process of randomisation was poorly described
(“Children divided into 2 groups”). Many years ago the use of the
word randomisation was not frequently used particularly in non-
English speaking countries. This might have introduced an inclu-
sion bias in a review where many studies were conducted in the
1960s and 1970s. In order to conduct sensitivity analyses where
the impact of including or excluding the non-randomised stud-
ies can be evaluated, The Cochrane Collaboration’s protocol may
need to be revised.
We also tried to retrieve unreported data by contacting study au-
thors but we were not able to include 14 studies for which infor-
mation on the randomisation process or main results was lacking.
Those papers were published during the 60s and 70s, before the
publication of the CONSORT Statement, and so important data
were omitted. The many years since publication made it impossi-
ble to obtain information from authors. If data from these studies
were available, the results of this review would have been more
powerful and informative.
Finally, it is also important to note that the overall study quality
ratings fell in the low range; this could also have introduced a bias
into the results. The lack of important information in many trial
reports has resulted in categorisations of ’unclear’ risk of bias.
Studies did not use the exact same interventions, follow the same
protocol or report the same outcome. Thus, we restricted our pool-
ing to interventions that were very similar, and could appropri-
ately be pooled. Moreover, we calculated prevented fractions (PFs)
by combining several indexes; two different measures may not be
exactly alike and this may have introduced a measurement bias.
The external validity of the review can be considered as good; the
included studies gave data for various participant ages, baseline
levels of caries or countries.
We have investigated sources of heterogeneity in this review, exam-
ining factors related to participants and study characteristics. The
calculation of the estimated PFs was done separately for different
lengths of follow-up. Nevertheless, due to a small number of data
we were not able to conduct a meta-regression or to create other
subgroups.
A final comment is that the reported studies did not conduct
intention-to-treat (ITT) analyses. This recent approach to analysis
of randomised controlled trials may assist in reducing bias created
when only those subjects who completed the trial are included in
the final analysis.
Agreements and disagreements with other
studies or reviews
The results of the present review are in accordance with the con-
clusion of recent reviews (Espelid 2010; Ismail 2008) that have
examined the evidence regarding the effectiveness of fluoride sup-
plements in preventing caries. In a recent review (Ismail 2008),
12 trials evaluating the preventive effect of fluoride supplements
were considered. The authors concluded that there is weak evi-
dence that the use of fluoride supplements prevents dental caries
in primary teeth. They found some evidence that fluoride supple-
ments prevent caries in permanent teeth. The Swedish Council
on Technology Assessment in Health Care has also recently con-
ducted a systematic review on the effectiveness of different mea-
sures for caries prevention. Five studies related to the effect of fluo-
ride supplements on permanent teeth were included in this review.
The authors concluded that there was no clear evidence that the
use of fluoride supplements prevents dental caries on permanent
teeth. They noticed that the only study that found a significant
preventive effect of fluoride supplements was an old study con-
ducted during the 70s (Swedish Council 2002). The American
Center for Disease Control (CDC) also has published in 2001
recommendations for using fluoride to prevent and control dental
caries. They concluded that the quality of evidence to support use
of fluoride supplements by children aged less than 6 years was low.
They selected three randomised controlled trials and concluded
that they provided good evidence about the preventive effect of
fluoride supplements on dental caries among children aged be-
tween 6 and 16 years in programs conducted in schools (CDC
2001).
This review provides little information about the risk of adverse
effects. However, the use of fluoride supplements by young chil-
dren is usually known to be a risk factor for dental fluorosis. A
systematic review has investigated the impact of the use of fluoride
supplements in communities without water fluoridation during
the period of tooth development (< age 6) on the risk of dental
fluorosis (Ismail 1999). Twenty-four studies that assessed dental
fluorosis in children who had used fluoride supplements earlier in
their life were included. Among them, 14 studies (10 cross-sec-
tional and 4 follow-up studies) had data that allowed a quantita-
tive estimation of the risk of dental fluorosis. A consistent associ-
ation between the use of fluoride supplements and dental fluoro-
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sis was noticed in the 24 studies. The meta-analyses of the cross-
sectional studies estimated that the odds ratio of dental fluorosis
in users of fluoride supplements compared with non-users ranged
between 2.4 and 2.6. The meta-analyses of the follow-up studies
estimated that the risk ratio in long-term users was between 5.5
and 12.2. This review stated that in communities with no water
fluoridation, the use of fluoride supplements during the first 6
years of life was associated with a significant increase in the risk
of developing dental fluorosis. Evidence is weak as this statement
is derived mainly from the results of cross-sectional surveys. Ret-
rospective and cohort studies have found a strong link between
regular intake of fluoride supplements and the risk of developing
fluorosis. Conversely, monitoring of children who participated in
clinical studies evaluating the preventive effect of fluoride supple-
ments showed almost no difference in the prevalence and sever-
ity of fluorosis between the children from the intervention or the
control group. Some bias might explain differences in the results
from cross-sectional surveys and clinical studies. Nevertheless, it
must be noted that in clinical studies, the administration of flu-
oride supplements was supervised and took place through struc-
tured programs. Retrospective or cohort studies report data which
mainly relate to children who took supplements on an individual
basis. In this case, there was no supervision nor control of com-
pliance or doses of fluoride administered. The fluorosis risk from
fluoride supplementation could be lower when fluoride supple-
ments are administered within school programs rather than on an
individual basis (Banting 1999).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review suggests that the use of fluoride supplements is asso-
ciated with a reduction in caries increment when used in perma-
nent teeth and when compared with no other preventive fluoride
treatment. For children aged 5 to 12 years at baseline, the use of
fluoride supplements was associated with a 24% (95% confidence
interval 16% to 33%) reduction in decayed,missing and filled sur-
faces (D(M)FS). When the fluoride supplements were compared
with the use of topical fluorides (toothpastes, varnishes, rinses) or
with the use of other preventive measures (xylitol lozenges), there
was no differential effect. Many of the studies included in the re-
view had been conducted at a time when topical fluorides were
not widely used. There is a lack of evidence from the review to
make actual good recommendations because, at the present time,
the effect of fluoride supplements in children using fluoride tooth-
pastes on a regular basis would probably be limited.
For children aged less than 5 years, there was weak evidence that
the use of fluoride supplements prevents dental caries in primary
teeth. From one study, no caries-inhibiting effect was observed
while in another study, the use of fluoride supplements was as-
sociated with a substantial reduction in caries increment. When
fluoride supplements were compared with the use of topical fluo-
rides (toothpastes, varnishes, rinses), there was no differential ef-
fect on deciduous teeth. Unfortunately, the review provides little
information on the adverse effects such as enamel fluorosis. The
ratio benefit/risk of fluoride supplementation was thus unknown
for young children (< 6 years). Based on these results, it may not be
appropriate to recommend the ingestion of fluoride supplements
in children under 6 years as there is considerable uncertainty sur-
rounding the ratio benefit/risk of this preventive intervention.
Implications for research
The quality of the trials included in this review was generally low
and many reports lacked important data or methodological infor-
mation. This is probably due to the fact that most of the studies
were relatively old. Based on the results of this review, several rec-
ommendations could thus be made for conducting and reporting
clinical trials in order to facilitate future systematic reviews and
meta-analyses. First, study authors should include the numbers,
means and standard deviations for all of the group outcome mea-
sures. Second, authors should use caries increment data measured
at the surface level (DMFS) and give total caries increment cal-
culated for all teeth and all types of surfaces in order to facilitate
comparisons between studies. Third, authors should carefully de-
scribe the methodology used to ensure the quality of the study
concerning randomisation, allocation concealment or blindness
in outcome assessment. This information is necessary to provide
an objective measure of the internal validity of the included trials,
and is critical for making well-informed interpretations of review
findings. Fourth, in case of randomisation based on clusters, this
should be clearly reported so that the possibility of bias due to
important differences between clusters can be checked.
For older children (> 6 years): Further randomised comparisons
of fluoride supplements and placebo on permanent teeth would
be impossible to conduct today in developed countries as the vast
majority of the children brush their teeth with fluoridated tooth-
pastes. It would not be justifiable to ask children not to use flu-
oridated toothpastes during the study period as the evidence for
their efficacy is high. The situation could be different in develop-
ing countries where accessibility to fluoridated toothpastes is not
ensured. Comparisons of fluoride supplements with other topi-
cally applied fluoride interventions on permanent teeth would not
provide more useful information. Comparisons of fluoride sup-
plements with other preventive measures would perhaps be more
interesting as we found only one study in this review allowing this
kind of comparison. The respective efficacy of the combination
of topical fluorides plus fluoride supplements against topical fluo-
rides alone or against topical fluorides plus other preventive mea-
sures has not been explored in this review and would also need to
be evaluated.
28Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For younger children (< 6 years): Future studies would be useful
to determine the relative effectiveness of different fluoride sources
such as fluoride supplements, applications of fluoride varnish, daily
use of fluoridated toothpaste or a combination of these modali-
ties. On deciduous teeth, there was no clear evidence that fluoride
supplements have a caries-inhibiting effect when compared with
no fluoride supplement. There was little evidence from studies
which have compared fluoride supplements with other fluoride
interventions (toothpastes, varnishes, rinses). There was also little
information on the effects of fluoride toothpaste in the decidu-
ous dentition particularly for fluoride concentrations above 1000
ppm (Walsh 2010). It would thus be interesting to evaluate the
respective efficacy and safety of these fluoride sources. This kind
of study would need a long follow-up as it would be necessary to
assess caries incidence in deciduous teeth as well as dental fluorosis
and caries in erupting permanent teeth.
Many countries or international institutions recommend the use
of fluoride supplements for children who are at high caries risk.
The effect of the different supplementation regimens proposed
(doses, age at start, level of risk, modalities of administration) is
unknown and would need evaluation. Compliance and adherence
of the children and of their families would probably be a crucial
factor in determining the efficacy of those regimens in high risk
populations. Moreover, the modalities of administration of fluo-
ride supplements are key factors for the future studies. The review
did not determine precisely if the effect of fluoride supplements
was pre- or posteruptive or both. Now the common view is that
it is through the posteruptive (topical) effect that fluorides have
caries preventive action. In this context, ingestion of the supple-
ments is not necessary nor needed to obtain a preventive effect as
the topical application of fluoride compounds is all that is required
to provide preventive effect on dental caries.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aasenden 1972
Methods Random allocation on an individual basis, allocation concealment unknown
Double blind
Placebo-controlled
APF compared to NaF and placebo tablets
Study duration 3 years
33.6% drop out after 3 years; attributable to “reasons unrelated to the program”
The number of children attributed to each group is not given. Percentage of drop out
per group cannot be calculated
Participants 362 children analysed after 3 years (available at final examination)
Age at start: 8 to 11 years
Surfaces affected at start: 7.32 to 8.58 DFS
Exposure to other fluoride: Majority of children with a “history of some kind of topical
fluoride”. No water fluoridation (0.1 ppm fluoride in the water supply)
Year study began: Not reported, before 1972
Location: Massachusetts, USA
Interventions Fluoride supplements diluted in a liquid resulting in a solution
The liquid contained a surfactant (0.01% polysorbate 80) to favour contact with the
tooth surfaces
Fluoride: 0.02 percent F as NaF
APF tablets: 0.1 M phosphate at pH 4
Solution administered daily at school (138 to 173 days per year)
Children instructed to hold 5 ml in the mouth for 1 min and then swallow
No information or data on compliance
Outcomes Baseline mean DFS, DFT, number of sound teeth, number of sound surfaces
Number of teeth erupted during the study
Caries increment (DFS, DFT) reported at 1, 2 and 3 years of follow-up
Mean number of extracted teeth after 3 years
Mean DFS increment for surfaces present initially and that erupted during the study
DFS increment after 3 years according to oral hygiene status
Fluoride concentrations of biopsies from maxillary central incisors and canines
Notes Participants randomised (n = 545)
Baseline characteristics “balanced”: at start, no difference in age, sex ratio, caries preva-
lence (DFS, DFT), mean number of sound teeth or surfaces between the groups
Clinical caries assessment made by one examiner
Clinical diagnostic threshold = “surface discontinuity penetrable by explorer”
Radiographic assessment using posterior bitewings and radiograph of anterior teeth in
cases of doubt
Radiographic diagnostic threshold = discontinuity in normal enamel radiolucency
Reliability: Not reported
Account for reversals: Not reported
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Aasenden 1972 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “three groups were formed by ran-
dom allocation of the participants”
Comment: Not enough information pro-
vided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quotes: “all three
solutions were flavoured”, “the group affil-
iations were unknown to dental personnel
and participants throughout the study and
the examinations were done in random or-
der. Previous findings were not available to
the personnel during the examinations”
Comment: Blind outcome assessment and
use of placebo described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quotes: “all data refer to the 109, 114 and
139 subjects remaining in groups 1,2,3 at
the final examination”
Drop out for length of follow-up: 33.6%
in 3 years
Drop out by group: Unknown
Reasons for losses: “due to a variety of rea-
sons unrelated to the dental program”
Comments: Numbers lost moderate but %
of drop out per group not given. Caries data
used in the analysis pertain to continuous
participants
Selective reporting (reporting bias) Low risk Outcomes reported:
Baseline mean DFS, DFT, number of
sound teeth, number of sound surfaces
Number of teeth erupted during the study
Caries increment (DFS, DFT) reported at
1, 2 and 3 years of follow-up
Mean number of extracted teeth after 3
years
Mean DFS increment for surfaces present
initially and that erupted during the study
DFS increment after 3 years according to
oral hygiene status
Fluoride concentrations of biopsies from
maxillary central incisors and canines
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Aasenden 1972 (Continued)
Comment: All prespecified outcomes (in
’Methods’) were reported. Final mean DFS
and DFT not available
Other bias Unclear risk Comment: Initial caries indexes appear bal-
anced (DFS: 7.99 in controls and 7.32 to
8.58 in treated children). Reliability of out-
come assessment is not reported. There is
no indication of contamination or co-in-
tervention
DePaola 1968
Methods Random allocation on an individual basis, allocation concealment unknown
Double blind
Placebo-controlled
APF compared to placebo tablets
Study duration 2 years
18.6% drop out after 2 years; mainly attributable to the moving of families
No differential group losses
Participants 266 children analysed after 2 years (available at final examination)
Age at start: 101 months
Surfaces affected at start: 3.90 to 4.45 DFS
Exposure to other fluoride: No history of exposure to fluoride supplements or fluoridated
water (0.07 ppm fluoride in the water supply)
Year study began: Not reported, before 1968
Location: Boston, Massachusetts, USA
Interventions Fluoride tablets (NaF 2.2 mg) vs non-fluoride tablets (all tablets with sodium biphos-
phate, hexamic acid, mannitol)
Tablets administered daily at school
Tablets chewed, swished around the mouth and swallowed
The mean number of tablets ingested was 149.4 the first year (113 to 159) and 159.5
during the second year (116 to 168)
Outcomes Baseline mean DFS, mean number of surfaces available
Caries increment reported at 10 and 24 months follow-ups
MeanCrude and netDFS,DFT increments,mean number of teeth and surfaces erupting
during the study period for all teeth and surfaces
Mean DFS increment for surfaces that erupted during the study
Notes Participants randomised (n = 327)
Baseline characteristics “balanced”: at start, no difference in age, caries prevalence (DFS)
, number of surfaces available between the groups (no statistical test)
Clinical caries assessment made by one examiner, diagnostic threshold = “surface discon-
tinuity penetrable by explorer”
Radiographic assessment (2 posterior bitewings) by one examiner; diagnostic threshold
= discontinuity in normal enamel radiolucency
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DePaola 1968 (Continued)
Reliability: Not reported
Account for reversals: Reversal rates in surfaces between the 1st, 2nd and 3rd examination
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “children were assigned at random
into two groups”
Comment: Not enough information pro-
vided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quotes: “fluoride tablets and tablets with-
out fluoride were similar in taste and
appearance”, “the identity of agents and
the group affiliation of subjects were un-
known todental personnel andparticipants
throughout the program”, “ the test and
control tablets were contained in colour-
coded wide-mouthed bottles of 500 and
were removed with specially made forceps
by a dental assistant who gave them to each
pupil”
Comment: Blind outcome assessment and
use of placebo described. Test and control
tablets stored in different types of bottles
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quotes: “all data presented refer to the 130
treatment and 136 control subjects who
were continuous participants in the inves-
tigation”
Drop out for length of follow-up: 18.6%
in 2 years
Drop out by group: 32/162 children miss-
ing in fluoride group and 29/165 in non-
fluoride group
Reasons for losses: “subjects losses were at-
tributable to themoving of families or other
reasons generally unrelated to dental pa-
rameters”
Comments: Numbers lost were low. No
differential loss between groups. Caries
data used in the analysis pertain to contin-
uous participants
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DePaola 1968 (Continued)
Selective reporting (reporting bias) Low risk Outcomes reported:
Baseline mean DFS, mean number of sur-
faces available
Caries increment reported at 10 and 24
months follow-ups
Mean crude and net DFS, DFT incre-
ments, mean number of teeth and surfaces
erupting during the study period for all
teeth and surfaces
Mean DFS increment for surfaces that
erupted during the study
Comment: All prespecified outcomes (in
’Methods’) were reported. Final mean DFS
and DFT not available
Other bias Unclear risk Comment: Initial caries indexes appear bal-
anced (DFS: 4.09 in controls and 4.41 in
treated children). Reliability of outcome as-
sessment is not reported. There is no indi-
cation of contamination or co-intervention
Driscoll 1974
Methods Random allocation on an individual basis, allocation concealment unknown
Double blind
Placebo-controlled: Fluoride tablet once a day compared with placebo tablet once a day
and with Fluoride tablet twice a day
Study duration 6 years
38.1% drop out after 30 months, 48.8% after 55 months and 57.6% after 6 years
Reason for attrition: Not reported
No differential group losses
Participants 640 children analysed after 30 months
Age at start: 6.6 years
Surfaces affected at start: 1.07 to 1.40 DMFS
Exposure to other fluoride: < 0.3 ppm fluoride in the water
Year study began: 1969
Location: Wayne county, NC, USA
Interventions Fluoride tablet once a day vs fluoride tablet twice a day vs placebo tablet
On schooldays, 115 to 149 days/year
Fluoride tablets: APF, 1 mg F, NaF, pH = 4.5, M10 phosphate
Tablets chewed, rinsed for 30 seconds with the resulting solution and then swallowed
Compliance: 95% of the tablets used during the first year and 86% during the third
year, the percentage of tablets used was slightly lower in group C (82.9%) as compared
to groups A and B (93.9 and 92.1%)
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Driscoll 1974 (Continued)
Outcomes Baseline DMFS
Caries increment reported at 30 months, 55 months and 6 years (+ evaluation 2 and 4
years after discontinuation of the treatment)
DMFS increment (unadjusted and adjusted on baseline DMFS)
DMFS increment for teeth present at baseline and teeth erupting during the study
DMFS increment per type of surfaces (occlusal, buccolingual, mesiodistal)
Surfaces reversals in diagnosis
Percentage of tablets used
Distribution of the children according to fluorosis classification
Notes Participants randomised (n = 1034)
Baseline characteristics “balanced”: At start, no difference in age and sex but lower mean
DMFS in the group receiving fluoride tablets/twice a day
Clinical caries assessment made by 2 to 3 examiners, using the ADA’s conference on the
clinical testing of cariostatic agents (1968) diagnostic criteria
Reliability of clinical examination not reported but it is stated that “the examiners con-
tinued to calibrate their examining techniques throughout the survey.”
Account for reversals: Reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “the record forms of the study par-
ticipants placed into blocks according to
race, sex, number of erupted permanent
teeth. Within each block, the records were
randomly assigned to one of three study
groups”
Comment: Randomisation process partly
described
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quotes: “the examiners did not know the
group to which any child was assigned” and
“the tablets were packaged in colour-coded
bottles so that their identity was unknown
to the teachers and students”
Comment: Blind outcome assessment and
use of placebo described. Test and control
tablets stored in different types of bottles
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop out for length of follow-up: 38.1%
after 30 months, 48.8% after 55 months
and 57.6% after 6 years
Drop out by group after 30 months: 134/
345 children missing in the group F tablet
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Driscoll 1974 (Continued)
(1/day), 134/345 in the group F tablet (2/
day) and 126/344 the placebo tablet group
Reasons for losses: Not reported
Comments: Numbers lost were high. No
differential loss between groups. Caries
data used in the analysis pertain to contin-
uous participants
Selective reporting (reporting bias) Low risk Outcomes reported:
Baseline DMFS
Caries increment reported at 30 months,
55 months and 6 years (+ evaluation 2 and
4 years after discontinuation of the treat-
ment)
DMFS increment (unadjusted and ad-
justed on baseline DMFS)
DMFS increment for teeth present at base-
line and teeth erupting during the study
DMFS increment per type of surfaces (oc-
clusal, buccolingual, mesiodistal)
Surfaces reversals in diagnosis
Percentage of tablets used
Ditribution of the children according to
fluorosis classification
Comment: All prespecified outcomes (in
’Methods’) were reported. Final mean
DMFS not available
Other bias Unclear risk Comment: Initial caries scores appear bal-
anced but a lower DMFS was observed in
the group which received F tablets twice a
day (DMFS at baseline: 1.35 in the placebo
tablet group, 1.40 in the F tablet group -
once a day and 1.07 in the F tablet group
- twice a day). Reliability of outcome as-
sessment is not reported. Surface reversals
are reported. There is no indication of con-
tamination or co-intervention
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Heifetz 1987
Methods Random allocation on an individual basis, allocation concealment unknown
Single blind
Fluoride tablets compared with fluoride rinses and with both procedures
Study duration 8 years
36.3% drop out after 2 years, 51.9% after 5 years and 61% after 8 years
Reason for attrition, lost of subjects due to movement of families from the area
No differential group losses
Participants 1154 children analysed after 2 years
Age at start: 5 to 6 years
Surfaces affected at start: 0.24 DMFS, 4.73 dmfs
Exposure to other fluoride: < 0.3 ppm fluoride in the water, the majority of participants
had access to fluoride containing toothpastes
Year study began: 1981
Location: Springfield, Ohio, USA
Interventions Fluoride tablet vs fluoride rinse vs both procedures on schooldays
Rinse: Once a week, 0.2% NaF solution, 0.09% F
Tablet: One tablet chewed, rinsed and swallowed daily, neutral NaF, 1 mg F
Compliance: “children participated in average in more than 90% of the maximum
number of treatment offered. nearly identical in each group”
30 children excluded because they received treatment for less than 4 years on 5
After year 5, more harder tablets have been used
Outcomes Baseline mean DMFS, dmfs
Caries increment reported at 2, 5 and 8 year follow-ups
DMFS, dmfs increment
DMFS, dmfs increment per type of surface (occlusal, bucco-lingual, mesiodistal)
DMFS increment for early erupting and late erupting teeth
(+ evaluation of fluorosis 3 years after discontinuation of treatment)
Notes Participants randomised (n = 1640)
Baseline characteristics “balanced”: At start, no difference in age, sex and mean DMFS,
dmfs between groups
Clinical caries assessment made by 2 to 3 examiners, using the ADA’s conference on the
clinical testing of cariostatic agents (1968) diagnostic criteria
Reliability measured by comparing caries increment mean values obtained by each ex-
aminer, no statistical difference was found
Account for reversals: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “children were assigned randomly
to one of 3 groups”
Comment: Not enough information pro-
vided
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Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quotes: “the examiners were not aware of
the group assignments of the children”
Comment: Blind outcome assessment de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop out for length of follow-up: 29.6%
after 2 years, 51.9% after 5 years, 61% after
8 years
Drop out by group after 2 years: 164/544
children missing in the F rinse group, 165/
537 in the F tablet group and 157/559 in
the group with both procedures
Reasons for losses: “the predominant rea-
son for loss of subjects was movement of
the family from the Springfield area”
Comments: Numbers lost were high. No
differential loss between groups. Caries
data used in the analysis pertain to contin-
uous participants
Selective reporting (reporting bias) Low risk Outcomes reported:
Baseline mean DMFS, dmfs
Caries increment reported at 2, 5 and 8 year
follow-ups
DMFS, dmfs increment
DMFS, dmfs increment per type of surface
(occlusal, bucco-lingual, mesiodistal)
DMFS increment for early erupting and
late erupting teeth
(+ evaluation of fluorosis 3 years after dis-
continuation of treatment)
Comment: All prespecified outcomes (in
’Methods’) were reported. Final mean
DMFS and dmfs not available
Other bias Unclear risk Comment: Initial caries indexes appear bal-
anced (DMFS at baseline: 0.22 in F rinse
group, 0.30 in F tablet group and 0.19 in
F tablet + rinse group for children remain-
ing after two years). Reliability of outcome
assessment is not reported. Account for re-
versals or errors in clinical interpretation
are not reported. There is no indication of
contamination or co-intervention
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Holm 1975
Methods School classes randomly divided into 2 groups, cluster-randomised
Allocation concealment: Not reported
Single blind
Study duration 2 years
Fluoride chewable tablet compared with fluoride mouthrinse
11% drop out after 2 years
Reason for attrition: Not reported
No differential group losses
Participants 357 children analysed after 2 years
Age at baseline 11 to 12 years
Surfaces affected at start: 6.6 to 6.9 DFS
Exposure to other fluoride: Many schools at that time got fluoride mouthwash on a
weekly basis
Year study began: 1971
Location: Public schools in the city of Lund, Sweden
Interventions Fluoride chewable tablet vs fluoride mouthrinse
Fluoride tablets: on schooldays, 200 days/year, NaF, 0.42 mg F
Fluoride mouthrinse: Once a week as routine prevention in Sweden
Tablets distributed at school by teachers. No information on compliance
Outcomes Baseline: Mean number of surfaces erupted, mean number of decayed or filled surfaces
(DFS)
Caries increment reported after 2 years
DS increment
DS increment for occlusal and mesio-distal surfaces
Gingivitis and plaque
Notes Participants randomised (n = 401)
Baseline characteristics “balanced”: At start, no difference between the groups for the
number of teeth erupted and the number of carious or filled teeth
Clinical and radiographic caries assessment made by 2 examiners, using Koch’s (1967)
diagnostic criteria
Reliability of clinical examination not reported
Account for reversals: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “School classes were randomly di-
vided into two groups to make every age
group and school equally represented in the
two study groups”
Comment: Randomisation process partly
described, cluster
Allocation concealment (selection bias) Unclear risk No information provided
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Holm 1975 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quotes: “The assessing dentists at the time
of assessment had no knowledge regarding
group assignment”
Comment: Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout for length of follow-up: 11%after
2 years
Drop out by group after 2 years: 24/181
children missing in the test group, 20/220
in the control group
Reasons for losses: Not reported
Comments: Numbers lost were low. No
differential loss between groups. Caries
data used in the analysis pertain to contin-
uous participants
Selective reporting (reporting bias) Unclear risk Outcomes reported:
Mean number of surfaces erupted, mean
number of decayed or filled surfaces (DFS)
Caries increment reported after 2 years
DS increment
DS increment for occlusal and mesio-distal
surfaces
Gingivitis and plaque
Comment: Few outcomes were reported.
No final data for mean DS and DFS
Other bias Unclear risk Comment: Initial caries scores appear bal-
anced (DS at baseline: 6.9 in the tablet
group, 6.6 in the mouthwash group). Re-
liability of outcome assessment is not re-
ported. Surface reversals or errors in clin-
ical interpretation are not reported. There
is no indication of contamination or co-in-
tervention
Källestål 2000
Methods Random allocation on an individual basis, allocation concealment unknown
Not blind (field trial)
Study duration 5 years
Groups with information on toothbrushing, prescription of fluoride lozenges, semi-an-
nual applications of fluoride varnish, individual preventive appointments were compared
18.4% drop out after 5 years
Reason for attrition: Children moved from the area
No differential group losses
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Källestål 2000 (Continued)
Participants 925 children analysed after 5 years (available at final examination)
Age at start: 12 years
Children with a predicted high caries risk
Surfaces affected at start: 2.5 to 3.07 DMFS (for children who completed the study)
Exposure to other fluoride: All toothpastes fluoridated, fluoride consumption evaluated
by questionnaire (fluoride in water: > or < 1 ppm, use of F supplements, toothbrushing
habits)
Year study began: 1995
Location: 26 dental clinics, Sweden
Interventions Toothbrushing information vs prescription of fluoride lozenges vs fluoride varnish ap-
plications vs individual program
Toothbrushing information: Information on toothbrushing once a year at each dental
examination
Prescription of fluoride lozenges: 0.25 mg F, NaF, 3 to 6 tablets per day, sucking type
Fluoride varnish applications: NaF, 2.2% F, applied 3 times a week every 6 months after
professional cleansing of the teeth
Individual program: evaluation of oral hygiene status and counselling in dental hygiene,
oral hygiene and diet checked every 3 months, professional cleaning and fluoride varnish
applied every 3 months
All high risk children received sealants
Compliance was checked every year
31% of the children were judged as having a good compliance the in group “toothbrush-
ing information” , 62% in the group “fluoride lozenges”, 76% in the group “fluoride
varnish” and 65% in the group “individual program”. Criteria used to define compliance
varied from one group to another
Outcomes At baseline: living area and professional status in parents, mean DMFT, DMFS, DMFSe
(enamel), DMFSa (approximal)
Caries increment reported at 4 years: DMFS, DMFSe increment
Mean DMFS and DMFSe (enamel) annual values for each of the 5 years of study
Cost-effectiveness analysis: Mean treatment time, mean treatment cost, total treatment
costs, total patient and family related costs
Multivariate analysis of DMFS and DMFSe (enamel) increment as dependant variables
with socioeconomic status, ethnicity, participation in earlier programs, sealants use, self-
administered fluoride, eating sweets, toothbrushing interval and preventive regimen as
independent variables
Notes Participants randomised (n = 1134)
Baseline characteristics “balanced”: “At start, no difference in mean DMFS between
groups (no test)”
Clinical and radiographic caries assessment made the dentists from the 26 clinics, using
CK assessment diagnostic criteria (Flink 1999, Kallestal 2000)
Reliability of caries assessment: Inter- and intraexaminer reproducibility tests with Kappa
varying from 0.64 to 0.88
Reversals were included in the calculation of caries increment
Risk of bias
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Källestål 2000 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “Each high-risk child was ran-
domly assigned to one of four preventive
programs”
Comment: Not enough information pro-
vided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
High risk Quotes: “The collaboration with the clini-
cians and their crucial contribution to the
data collectionmade it impossible to do the
caries registration in a blinded fashion”
Comment: Examiners not blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop out for length of follow-up: 18.4%
drop out after 5 years
Drop out by group: Number of children in
each group at baseline, not reported
Reasons for losses: “Themost common rea-
son for dropping out was that child had
moved from the area. Some of the examina-
tion records (30%) of those lost to follow-
up during all years were located and their
mean caries incidence over the whole study
period was the same as that of the study
group.”
Comments: Numbers lost unclear. Caries
data used in the analysis pertain to partic-
ipants present at the time of each annual
examination
Selective reporting (reporting bias) Unclear risk Outcomes reported:
At baseline: Living area and professional
status in parents, meanDMFS andDMFSe
(enamel), DMFT, DMFSa (approximal)
Caries increment reported at 4 years:
DMFS, DMFSe increment
MeanDMFS andDMFSe (enamel) annual
values for each of the 5 years of study
Cost-effectiveness analysis: Mean treat-
ment time,mean treatment cost, total treat-
ment costs, total patient and family related
costs
Multivariate analysis of DMFS and
DMFSe(enamel) increment as dependant
variables with socioeconomic status, eth-
nicity, participation in earlier programs,
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Källestål 2000 (Continued)
sealants use, self administered fluoride, eat-
ing sweets, toothbrushing interval and pre-
ventive regimen as independent variables
Comments: Many data but annual caries
increments not available except at 4 years
Other bias Low risk Quotes: “all previous programmeswere dis-
continued as no preventive programmes in-
cluding sealant placement were to be con-
ducted other than those randomly assigned
within the study. Important factors such as
use of fluoride in the development of caries
were followed throughout the study by us-
ing questionnaires and reports from each
clinic.”
Comment: Contamination by other pre-
ventive programs was avoided and poten-
tial co-intervention carefully considered
Comment: Initial caries scores appear bal-
anced (2.93 in the information group, 2.50
in the F lozenges group, 3.07 in the F var-
nish group, 2.71 in the individual program
group). Reliability of outcome assessment
is reported. Surface reversals are considered
in the calculation of net caries increment.
There is no indication of contamination or
co-intervention
Lin 2000
Methods Random allocation on an individual basis, allocation concealment unknown
Single blind
Study duration 2 years
Fluoride drops compared with fluoride tablets and with no treatment
17.8% drop out after 2 years
Reason for attrition: Not reported but “children were excluded if a 10-day dosage re-
mained as a residual amount after each 3 month period”
Slightly lower attrition in the fluoride tablet group
Participants Children with cleft lip and/or palate
115 children analysed after 2 years (available at final examination)
Age at start: 22 to 26 months
At start: 0.18 to 0.34 dmft, 0.23 to 0.34 dmfs
Exposure to other fluoride: < 0.1 ppm fluoride in the water, toothbrushing without
fluoridated toothpastes
Year study began: Not reported
Location: Orthodontic clinic, Kaohsiung Medical centre, Taiwan
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Lin 2000 (Continued)
Interventions Fluoride drops vs fluoride tablets vs nothing
Fluoride drops, NaF, 1 drop = 0.25 mg F, 2 drops per day
Fluoride tablets, NaF, 1 tablet = 0.5 mg F, 1 tablet per day
All children recalled every 3 months for oral hygiene procedure
Tablets and drops administered at home by parents. Compliance was checked at each
recall appointment. Subjects were excluded if a 10-day dosage remained as residual
amount after each period. No data provided on compliance
Outcomes At baseline: dmft, dmfs
Caries increment reported after 2 years
dmft, dmfs increment
Final dmft, dmfs
Notes Participants randomised (n = 140)
Baseline characteristics “balanced”: At start, no difference between the groups for mean
dmft and dmfs
Clinical caries assessment made by 2 examiners, using the modified method of Radike’s
(1972) diagnostic criteria
Reliability: Interexaminer was tested by computing the Pearson correlation coefficient (r
= 0.90)
Account for reversals: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “subjects were randomly assigned
into a control group of no fluoride supple-
ments, a fluoride tablet group and a liquid
tablet group”
Comment: Not enough information pro-
vided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quotes: “examiners were blind to the as-
signments”
Comment: Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop out for length of follow-up: 17.8%
after 2 years
Drop out by group after 2 years: 10/44 chil-
dren missing in the control group, 5/46 in
the F tablet group and 10/50 in the F liquid
group
Reasons for losses: Not reported
Comments: Numbers lost were low. Slight
differential loss between groups. Caries
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Lin 2000 (Continued)
data used in the analysis pertain to contin-
uous participants
Selective reporting (reporting bias) Low risk Outcome reported:
At baseline: dmft, dmfs
Caries increment reported after 2 years
dmft, dmfs increment
Final dmft, dmfs
Comment: All prespecified outcomes (in
’Methods’) were reported
Other bias Unclear risk Comment: Initial caries levels appear bal-
anced (dmfs at baseline: 0.34 in the tablet
group, 0.23 in the drop group and 0.27 in
the control group). Reliability of outcome
assessment is not reported. Surface rever-
sals or errors in clinical interpretation are
not reported. There is no indication of con-
tamination or co-intervention
O’Rourke 1988
Methods Pragmatic study evaluating cost appraisal
Random allocation on an individual basis, allocation concealment unknown
Single blind
Study duration 3 years
Fluoride tablets compared with no treatment
24.5% drop out after 2 years and 31.2% after 3 years
Reason for attrition: 6 withdrawn and others leaving the schools
No differential group losses
Participants 529 children analysed after 3 years (available at final examination)
Age at start: 5 years and 3 months
At start: 3.32 to 3.66 dmft
Exposure to other fluoride: Not reported
Year study began: Not reported, before 1988
Location: 22 primary schools, Manchester, UK
Interventions Fluoride tablets vs nothing
Fluoride tablets, NaF, 1 mg F, 1 tablet per school day
Tablets distributed to the children at school, no information on compliance
Outcomes At baseline: dmft, DMFT not available
Caries increment reported after 1, 2 and 3 years
dmft, DMFT increment
Number of children with toothache, having local/general anaesthesia and fear at final
examination
Evaluation of costs (Resource Related Index)
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O’Rourke 1988 (Continued)
Final examination: dmft, DMFT not available
Notes Participants randomised (n = 769)
Baseline characteristics “balanced”: At start, no difference between the groups for mean
dmft
Clinical caries assessment made by one examiner, using the Downer’s (1979) diagnostic
criteria
Reliability of caries assessment: Not reported
Account for reversals: Not reported
Results calculated for all eligible children without considering compliance
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “childrenpaired on socioeconomic
factors and randomly allocated to control
or test groups within each pair”
Comment: Randomisation process partly
described
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quotes: “the examinationswere carried out
by an examiner unconnected with the con-
duct of the trial and were blind”
Comment: Blind outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop out for length of follow-up: 24.5%
drop out after 2 years and 31.2% after 3
years
Drop out by group: 70/336 children miss-
ing in the control group, 60/323 in the F
tablet group between year 1 and year 3
Reasons for losses: 6 withdrawn and others
leaving the schools
Comments: Numbers lost were moderate.
No differential loss between groups. Caries
data used in the analysis pertain to contin-
uous participants
Selective reporting (reporting bias) Unclear risk Outcomes reported:
Caries increment after 1, 2 and 3 years
dmft, DMFT increment
Number of children with toothache, hav-
ing local/general anaesthesia and fear at fi-
nal examination
Evaluation of costs (Resource Related In-
dex)
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O’Rourke 1988 (Continued)
Comments: Baseline and final dmft and
DMFT not available. Caries increment
measured at the tooth level only
Other bias Unclear risk Comment: Initial caries levels appear bal-
anced (dmft at baseline: 3.66 in the tablet
group, 3.32 in the control group). Reliabil-
ity of outcome assessment is not reported.
Reversals or errors in clinical interpretation
are not reported. There is no indication of
contamination or co-intervention
Petersson 1985
Methods Random allocation on an individual basis, allocation concealment unknown
Single blind
Study duration 2 years
Administration of “fluoride tablets + placebo dentifrice” compared with “fluoride denti-
frice”, “fluoride varnish + placebo dentifrice” and “fluoride varnish + fluoride dentifrice”
Drop out: 5% after 2 years
Reason for attrition: Not reported
No differential group losses
Participants 357 children analysed after 2 years (available at final examination)
Age at start: 3 years
Surfaces affected at start: 0.9 dfs
Exposure to other fluoride: water 0.2 ppm F
Year study began: Before 1978
Location: City of Uddevalla, Sweden
Interventions Fluoride tablets + placebo dentifrice vs fluoride dentifrice vs fluoride varnish + placebo
dentifrice vs fluoride varnish + fluoride dentifrice
Fluoride tablets: 0.25 mg F, NaF, 2 tablets per day, sucking type
Fluoride varnish: NaF, 2.2% F, applied every 6 months
Fluoride dentifrice: NaF, 0.025% F, used twice a day
All groupswith information about dental health care, dietary counselling andoral hygiene
instructions
Products regularly supplied at the dental clinic and administered at home. No data or
information on compliance
Outcomes At baseline: sex, mean dfs, distribution according to the number of dfs
Caries increment reported at 1 and 2 years
Caries increment: Mean number of new manifest carious tooth surfaces (ds) (no SD)
and distribution according to the number of new ds
Mean number of new manifest carious tooth surfaces (ds) (no SD) and distribution
according to the number of new ds per type of surface (occlusal, bucco-lingual, approx-
imal)
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Petersson 1985 (Continued)
Notes Participants randomised (n = 376)
Baseline characteristics “balanced”: At start, no difference between groups for the number
of dfs (no SD, no test)
Clinical and radiological (if necessary) caries assessment made by 2 examiners, using
Koch’s (1967) diagnostic criteria. Diagnostic threshold = manifest carious lesion
Reliability of caries assessment: Not reported
Account for reversals: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “children listed in official pop-
ulation list and numbered I to IV con-
secutively and in this way 4 groups were
formed”
Comment: Randomisation process partly
described
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quotes: “examiners at the clinical examina-
tion not aware to which group the child be-
longed” but “two dentists were responsible
for the examinations of the children, intro-
ducing the prophylactic programs, neces-
sary restorative treatments and follow-up”
Comment: Blind outcome assessment not
clearly ensured
Incomplete outcome data (attrition bias)
All outcomes
Low risk Drop out for length of follow-up: 5% after
2 years
Drop out by group after 2 years: 5/96 chil-
dren missing in F tablet + placebo denti-
frice group, 4/85 in F dentifrice group, 6/
98 in F varnish + placebo dentifrice group
and 4/88 in F varnish + F dentifrice group
Reasons for losses: Not reported
Comments: Numbers lost were low. No
differential loss between groups. Reasons
for losses not reported. Caries data used in
the analysis pertain to continuous partici-
pants
Selective reporting (reporting bias) Unclear risk Outcomes reported:
At baseline: sex, mean dfs, distribution ac-
cording to the number of dfs
Caries increment reported at 1 and 2 years
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Petersson 1985 (Continued)
Caries increment: Mean number of new
manifest carious tooth surfaces (ds) (no
SD) and distribution according to the
number of new ds
Mean number of new manifest carious
tooth surfaces (ds) (no SD) and distribu-
tion according to the number of new ds per
type of surface (occlusal, bucco-lingual, ap-
proximal)
Comment: Caries increment measured by
the “Mean number of newmanifest carious
tooth surfaces (ds)”. Standard deviationnot
available. Final dfs not available
Other bias Unclear risk Comment: Initial caries levels appear bal-
anced (dfs at baseline: 0.9 in all 4 groups).
Reliability of outcome assessment is not re-
ported. Reversals or errors in clinical inter-
pretation are not reported. There is no in-
dication of contamination or co-interven-
tion
Poulsen 1981
Methods Random allocation on an individual basis, allocation concealment unknown
Double blind
Study duration 3 years
Fluoride lozenge and placebo rinse compared with fluoride rinse and placebo lozenge
25.5% drop out after 3 years
Reason for attrition: Moved to non-involved schools
No differential group losses
Participants 499 children analysed after 3 years (available at final examination)
Age at start: 7 and 11 years
Surfaces affected at start: 2.01 to 2.27 DMFS (age 7) and 4.73 to 4.90 DMFS (age 11)
Exposure to other fluoride: < 0.25 ppm fluoride in the water
Year study began: Not reported, before 1981
Location: Region of Aarhus, Denmark
Interventions Fluoride lozenge and placebo rinse vs fluoride rinse and placebo lozenge
Fluoride rinse: 10 ml, 0.2% neutral NaF, fortnightly, on schooldays (40 rinses per child
for the study period)
Fluoride lozenges: Chewable, with 536 mg sorbitol, NaF (1.1 mg), one per day, on
schooldays (450 lozenges per child for the study period)
Lozenges and rinses administered at school
Children received 90% of the maximal number of Lozenges and 80% of the rinses (100
weeks or 500 schooldays)
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Poulsen 1981 (Continued)
Outcomes At baseline: mean DMFS, age, number of erupted surfaces for all teeth (per age group:
7, 11 years at baseline)
Caries increment reported at 3 years
DMFS increment given separately per age group (7, 11 years) and for teeth erupted at
baseline or erupting during the study
DMFS increment on proximal surfaces of premolars and molars in older children (age
11) for teeth erupted and erupting during the study
Distribution of the children according to age (7, 11 years), baseline DMFS (0, 1-2, > 3)
, number of erupted surfaces (< 30, > 30) and caries increment (< 1, > 2)
Distribution of the children according to consumption of lozenges and participation in
the rinsing program
Notes Participants randomised (n = 670)
Baseline characteristics “balanced”: At start, no differences in mean age, DMFS, number
of erupted surfaces between the groups (no statistical test)
Clinical and radiological (for older children) caries assessment made by 1 examiner,
using Moller & Poulsen (1973) diagnostic criteria. Diagnostic threshold = cavity: loss of
surface continuity
Reliability of caries assessment: Not reported
Account for reversals: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “on the basis of the clinical exam-
ination, children were stratified according
to DMFS and randomly distributed into 2
groups.”
Comment: Randomisation process partly
described
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quotes: “Lozenges and rinsing solutions
were coded and nobody knew the code (an-
swer from the author)”
Comment: Blind outcome assessment and
use of placebo described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop out for length of follow-up: 25.5%
drop out after 3 years
Drop out by group: 85/338 children miss-
ing after 3 years in fluoride lozenge +
placebo rinse group and 86/332 in fluoride
rinse + placebo lozenge group
Reasons for losses: Childrenmoved to non-
involved schools
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Poulsen 1981 (Continued)
Comments: Numbers lost were moderate.
No differential loss between groups. Caries
data used in the analysis pertain to contin-
uous participants
Selective reporting (reporting bias) Low risk OUtcomes reported:
At baseline: Mean DMFS, age, number of
erupted surfaces for all teeth (per age group:
7, 11 years at baseline)
Caries increment reported at 3 years
DMFS increment given separately per age
group (7, 11 years) and for teeth erupted at
baseline or erupting during the study
DMFS increment on proximal surfaces of
premolars andmolars in older children (age
11) for teeth erupted and erupting during
the study
Distribution of the children according to
age (7, 11 years), baseline DMFS (0, 1-2,
> 3), number of erupted surfaces (< 30, >
30) and caries increment (< 1, > 2)
Distribution of the children according to
consumption of lozenges and participation
in the rinsing program
Comment: Caries increment given sepa-
rately per age group and per status of teeth
eruption. Final DMFS not available
Other bias Unclear risk Comment: Initial caries indexes appear bal-
anced (DMFS in 7 years old children: 2.
18 in the F Lozenges + placebo rinse group
and 2.01 in the F rinse + placebo lozenges
group; DMFS in 11 years old children: 4.
73 in the F lozenges + placebo rinse group
and 4.81 in the F rinse + placebo lozenges
group). Reliability of outcome assessment
is not reported. Account for reversals or er-
rors in clinical and radiological interpreta-
tion are not reported. There is no indica-
tion of contamination or co-intervention
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Stecksen-Blicks 2008
Methods Random allocation on an individual basis, allocation concealment described
Double blind
Fluoride + xylitol compared with non-fluoride + xylitol lozenges
Study duration 2 years
28.1% drop out after 2 years
Reason for attrition: Relocation and violence of study protocol
No differential group losses
Participants 115 children analysed after 2 years (available at final examination)
Age at start: 10 to 12 years
Children with a predicted high caries risk (computerised risk assessment by the regular
dentists)
Surfaces affected at start: 2.1 to 2.9 DMFS (approximal) (for children who completed
the study)
Exposure to other fluoride: Use of fluoride toothpaste encouraged: “all the participants
were encouraged to brush their teeth with fluoridated toothpastes two times a day during
the entire study period”, fluoride in water supply < 0.3 ppm
Year study began: 2001
Location: Public dental clinic, city of Umea, Sweden
Interventions Fluoride xylitol lozenges (NaF, 0.5 mg) vs non-fluoride xylitol lozenges (all lozenges with
acid malic/malic acid and 422 mg xylitol)
Slow melting lozenges
Pots of lozenges sent every 3 months
2 lozenges, 3 times a day
Lozenges administered at home
Compliance was checked every 3 months. Non-consumed tablets were collected and
compliance evaluated by calculating the weight of remaining tablets
41% of the children were classified as having a good, 30% a fair and 29% a poor
compliance. Caries incidence did not vary according to compliance. Good compliance
was higher (48%) in the group “xylitol” as compared to the group “xylitol + fluoride”
(34%)
Outcomes At baseline: Mean DMFSa (approximal caries prevalence), DSe (enamel lesions on ap-
proximal surfaces)
Caries increment reported at 24 months
Caries increment: DMFSa (approximal caries prevalence) and DSe (enamel lesions on
approximal surfaces) increments
Final examination: Mean DMFSa (approximal caries prevalence), DSe (enamel lesions
on approximal surfaces)
Mean Caries increment and cumulative distribution frequency of caries increment
(DMFSa) among the subjects with good compliance
Notes Participants randomised (n = 160) but one reference group with high risk children who
refused to participate (n = 70) was also studied. This reference group was not considered
in the meta-analysis
Baseline characteristics “balanced”: At start, no significant difference in mean DMFSa
and DSe between the groups
Clinical and radiographic caries assessmentmade by two examiners. Diagnostic threshold
= “lesion within enamel (DSe)or passing into dentine (DMFSa)”. Caries increment
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Stecksen-Blicks 2008 (Continued)
(DMFSa, DSe) assessed from bitewing radiographs
Reliability in caries assessment: 50 sets of radiographs re-examined after 1 month in
order to check intra- and interexaminer reliability (Kappa = 0.85 to 0.89)
Account for errors or reversals: Not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “the subjects were randomly as-
signed to one of the two study groups and
each patient was given a code number.”
Comment: Randomisation process partly
described
Allocation concealment (selection bias) Low risk Quotes: “the randomisationwas performed
at the department for pharmaceutical test-
ing at the University Hospital Pharmacy
which kept the code list locked in a safe
during the entire project.” and “The code
was broken when the study was finalized
and all data were processed.”
Comment: Allocation concealment de-
scribed
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quotes: “code list locked in a safe during
the entire project.” and “ the study products
were slow-melting lozenges distributed in
identical pots and labelledwith the patient’s
individual code number.” and “The pots
were packed and labelled at the department
for pharmaceutical testing at theUniversity
Hospital Pharmacy.”
Comment: Blind outcome assessment and
use of identical lozenges in both groups de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Drop out for length of follow-up: 28.1%
after 2 years
Drop out by group: 21/80 childrenmissing
after two years in fluoride + xylitol group
and 24/80 in xylitol group
Reasons for losses: “relocation and violence
of study protocol” and “2 children aborted
treatment after 1 month because of stom-
achache.”
Comments: Numbers lost were moderate.
No differential loss between groups. Caries
data used in the analysis pertain to contin-
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Stecksen-Blicks 2008 (Continued)
uous participants
Selective reporting (reporting bias) Low risk Outcomes reported:
At baseline: Mean DMFSa (approximal
caries prevalence), Mean DSe (enamel le-
sions on approximal surfaces)
At final examination (24 months): DMFSa
(approximal caries prevalence) and DSe
(enamel lesions on approximal surfaces) in-
crements,meanDMFSa (approximal caries
prevalence), mean DSe (enamel lesions on
approximal surfaces)
Mean caries increment and cumulative dis-
tribution frequency of caries increment
(DMFSa) among the subjects with good
compliance
Comments: All prespecified outcomes (in
’Methods’) were reported. Caries incre-
ment measured only on approximal sur-
faces
Other bias Unclear risk Comments: Initial caries scores appear bal-
anced (DMFSa at baseline: 2.1 in xylitol
group and 2.9 in xylitol + fluoride group)
. Intra- and interexaminer reproducibility
reported and satisfactory. Account for re-
versals or errors in radiographic interpreta-
tion are not reported. There is no indica-
tion of contamination or co-intervention
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aasenden 1974 Random allocation not stated or indicated
No follow-up of the children
Abary-Murillo 1952 Random allocation not stated or indicated
Insufficient length of follow-up (6 months)
Adyatmaka 1996 Random allocation not stated or indicated
Allmark 1982 No random allocation
Barmes 1985 No random allocation
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(Continued)
Bibby 1955 Randomisation not ensured
Insufficient length of follow-up (12 to 14 months)
Binder 1958 Random allocation not stated or indicated
Blinkhorn 1981 In the test group home consumption of fluoride tablets was associated to chair side education while
no preventive intervention was applied to the control group
Insufficient length of follow-up (18 months)
Frankl 1972 Use of a fluoride solution (rinse) which was ingested
Did not fulfil the definition of fluoride supplements
Quotes: “the swallowing procedure avoided the problem of expectoration in the classroom.”
Grissom 1964 No random allocation
Hamberg 1971 Random allocation not stated or indicated
Hardwick 1981 Random allocation not stated or indicated
Hennon 1966 No longitudinal follow-up of the children
Randomisation not ensured
Hennon 1972 No random allocation
Hennon 1977 No longitudinal follow up of the children
Randomisation not ensured
Hippchen 1965 Random allocation not stated or indicated
Hu 1998 No random allocation
Kessler 1958 Random allocation not stated or indicated
Khambanonda 1983 No random allocation
Knychalsa-Karwan 1965 No random allocation
Kosenko 1984 Random allocation not stated or indicated
Larsen 1947 Random allocation not stated or indicated
Insufficient length of follow-up (4 months)
Leksell 2003 Abstract with no data
Caries increment and DMF values not given
Li 2005 No random allocation
Mann 1989 No random allocation
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(Continued)
Margolis 1967 Random allocation not stated or indicated
McCall 1985 Random allocation not stated or indicated
Pashaev 1993 Random allocation not stated or indicated
Pollak 1961 Random allocation not stated or indicated
Stephen 1978 No random allocation
Stephen 1990 No random allocation
Stones 1949 The number of children in each group is unknown. DMF indexes are not used. Caries increment
and PF values cannot be calculated
Strean 1946 Random allocation not stated or indicated
Insufficient length of follow-up (6 to 8 months)
Strubig 1982 Random allocation not stated or indicated
Szczygiel 1969 Random allocation not stated or indicated
Insufficient length of follow-up (19 months)
Wan 2000 Random allocation not stated or indicated
Wrzodek 1960 Random allocation not stated or indicated
Ziemnowicz-Glowacka 1960 Random allocation not stated or indicated
Characteristics of studies awaiting assessment [ordered by study ID]
Horowitz 1994
Methods Not yet assessed
Participants Not yet assessed
Interventions Not yet assessed
Outcomes Not yet assessed
Notes Not yet assessed
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Niedenthal 1957
Methods Random allocation: Not described
Allocation concealment: Unknown
Blindness in outcome assessment
NaF tablets compared with no treatment or placebo tablets (not stated)
Study duration 6 years
22% drop out after 3 years, 42% after 6 years
345 children attributed to the treatment group and 305 in the control group
Participants 508 children analysed after 3 years (1954) and 205 after 6 years (1957)
Age at start: 6 to 7 years
Surfaces affected at start: 0.22 DMFT
Exposure to other fluoride: not stated
Year study began: 1951
Location: Offenbach (Germany)
Interventions Fluoride tablet vs no treatment
Tablets administered on schooldays, under teacher supervision
Fluoride tablets: 0.5 mg F, 2 tablets per day
Outcomes Caries data at baseline (1951), after 3 years (1954) and 6 years (1957)
At baseline: Mean DMFT (no SD)
At final examinations: Mean DMFT (no SD)
Caries increments: DMFT increment (no SD)
Notes Participants randomised (n = 650)
Baseline characteristics “balanced”: unknown
Clinical caries assessment made by two examiners
Diagnostic threshold: Not stated
Reliability: Not reported
Account for reversals: Not reported
Prasertsom 1992
Methods Random allocation on an individual basis: The sample was divided into 2 groups with the equal number of children
using drawing lots method
Double blind
Placebo-controlled
NaF tablets compared to placebo tablets
Study duration 3 years
20.7% drop out after 3 years
Number of children attributed to each group: Unknown
Participants 493 children analysed after 3 years (available at final examination)
Age at start: 5 to 6 years and 7 to 8 years
Surfaces affected at start: 0.63 to 0.71 DMFS (5 to 6 years) and 1.55 to 1.83 DMFS (7 to 8 years)
Exposure to other fluoride: Children used fluoride mouthrinse 0.2% every 2 weeks according to the national oral
health promotion program
Year study began: 1987
Location: 2 schools in Bangkok, Thailand
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Prasertsom 1992 (Continued)
Interventions Fluoride tablets (NaF, 2.2 mg) vs non-fluoride tablets (flour tablets)
Tablets administered daily at school
Tablets chewed all over the mouth before swallowing
Outcomes Baseline and final DMFS (SD) by study group, age group
Percentage of children affected by caries in permanent and deciduous teeth, mean dfs by year of study, study group
Notes Participants randomised (n = 622)
Baseline characteristics “balanced”: mean DMFS
Clinical caries assessment made by 3 examiner teams. Each team consisted of 3 examiners
Calibration exercises were carried out for the examiners’ teams
Diagnostic threshold: Not stated
Reliability: Not reported
Account for reversals: Not reported
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D A T A A N D A N A L Y S E S
Comparison 1. Fluoride supplements vs no fluoride supplement
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 D(M)FS (24-36 months) 3 1240 Prevented fraction (Random, 95% CI) 0.24 [0.16, 0.33]
2 DMFS (55 months) 1 529 Prevented fraction (Random, 95% CI) 0.25 [0.12, 0.38]
3 DMFS (72 months) 1 437 Prevented fraction (Random, 95% CI) 0.28 [0.16, 0.41]
4 D(M)FT (24-36 months) 3 1208 Prevented fraction (Random, 95% CI) 0.29 [0.19, 0.39]
5 dmfs (24-36 months) 1 115 prevented fraction (Random, 95% CI) 0.73 [0.46, 0.99]
6 dmft (24-36 months) 2 696 Prevented fraction (Random, 95% CI) 0.46 [0.08, 0.83]
Comparison 2. Fluoride supplements vs Topical Fluoride
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 D(MF)S (24-36 months) 4 2047 Prevented fraction (Random, 95% CI) -0.10 [-0.25, 0.05]
2 DMFS (48 months) 1 472 Prevented fraction (Random, 95% CI) 0.0 [-0.20, 0.20]
3 DMFS (60 months) 2 971 Prevented fraction (Random, 95% CI) 0.06 [-0.18, 0.31]
4 DMFS (96 months) 1 Prevented fraction (Random, 95% CI) 0.21 [0.04, 0.38]
5 d(m)fs (24-36 months) 2 1051 prevented fraction (Random, 95% CI) 0.13 [-0.07, 0.33]
Comparison 3. Fluoride supplements vs other preventive measures
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 DMFS proximal (24-36 months) 1 115 Prevented fraction (Random, 95% CI) 0.0 [-0.59, 0.59]
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Comparison 4. Fluoride supplements vs no fluoride supplement (teeth erupted at baseline or erupting during
the study)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 D(M)FS 2 Prevented fraction (Random, 95% CI) Totals not selected
1.1 teeth erupted at baseline 2 Prevented fraction (Random, 95% CI) 0.0 [0.0, 0.0]
1.2 teeth erupting during the
study
2 Prevented fraction (Random, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Fluoride supplements vs no fluoride supplement, Outcome 1 D(M)FS (24-36
months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 1 Fluoride supplements vs no fluoride supplement
Outcome: 1 D(M)FS (24-36 months)
Study or subgroup Fluoride supplements
No Fluoride
supplement
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
DePaola 1968 (1) 130 136 0.23 (0.087) 25.4 % 0.23 [ 0.06, 0.40 ]
Aasenden 1972 (2) 114 70 0.27 (0.098) 20.0 % 0.27 [ 0.08, 0.46 ]
Aasenden 1972 (3) 109 70 0.3 (0.099) 19.6 % 0.30 [ 0.11, 0.49 ]
Driscoll 1974 (4) 202 106 0.1 (0.116) 14.3 % 0.10 [ -0.13, 0.33 ]
Driscoll 1974 (5) 197 106 0.27 (0.096) 20.8 % 0.27 [ 0.08, 0.46 ]
Total (95% CI) 752 488 100.0 % 0.24 [ 0.16, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.03, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 5.51 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours No F supplements Favours F supplements
(1) APF tablets
(2) NaF tablets (diluted)
(3) APF tablets (diluted)
(4) APF tablets, once a day
(5) APF tablets, twice a day
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Analysis 1.2. Comparison 1 Fluoride supplements vs no fluoride supplement, Outcome 2 DMFS (55
months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 1 Fluoride supplements vs no fluoride supplement
Outcome: 2 DMFS (55 months)
Study or subgroup Fluoride supplements
No Fluoride
supplement
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Driscoll 1974 (1) 179 91 0.2 (0.095) 47.3 % 0.20 [ 0.01, 0.39 ]
Driscoll 1974 (2) 168 91 0.3 (0.09) 52.7 % 0.30 [ 0.12, 0.48 ]
Total (95% CI) 347 182 100.0 % 0.25 [ 0.12, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours No F supplements Favours F supplements
(1) APF tablets, once a day
(2) APF tablets, twice a day
Analysis 1.3. Comparison 1 Fluoride supplements vs no fluoride supplement, Outcome 3 DMFS (72
months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 1 Fluoride supplements vs no fluoride supplement
Outcome: 3 DMFS (72 months)
Study or subgroup Fluoride supplements
No Fluoride
supplement
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Driscoll 1974 (1) 150 76 0.28 (0.09) 50.6 % 0.28 [ 0.10, 0.46 ]
Driscoll 1974 (2) 135 76 0.29 (0.091) 49.4 % 0.29 [ 0.11, 0.47 ]
Total (95% CI) 285 152 100.0 % 0.28 [ 0.16, 0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 4.45 (P < 0.00001)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours No F supplements Favours F supplements
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(1) APF tablets, once a day
(2) APF tablets, twice a day
Analysis 1.4. Comparison 1 Fluoride supplements vs no fluoride supplement, Outcome 4 D(M)FT (24-36
months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 1 Fluoride supplements vs no fluoride supplement
Outcome: 4 D(M)FT (24-36 months)
Study or subgroup Fluoride supplements
No Fluoride
supplement
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
DePaola 1968 (1) 130 136 0.21 (0.109) 20.5 % 0.21 [ 0.00, 0.42 ]
Aasenden 1972 (2) 114 69 0.26 (0.093) 28.2 % 0.26 [ 0.08, 0.44 ]
Aasenden 1972 (3) 109 69 0.32 (0.085) 33.8 % 0.32 [ 0.15, 0.49 ]
O’Rourke 1988 (4) 285 296 0.38 (0.118) 17.5 % 0.38 [ 0.15, 0.61 ]
Total (95% CI) 638 570 100.0 % 0.29 [ 0.19, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.35, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 5.89 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours No F supplements Favours F supplements
(1) APF tablets
(2) NaF tablets (diluted)
(3) APF tablets (diluted)
(4) NaF tablets
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Analysis 1.5. Comparison 1 Fluoride supplements vs no fluoride supplement, Outcome 5 dmfs (24-36
months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 1 Fluoride supplements vs no fluoride supplement
Outcome: 5 dmfs (24-36 months)
Study or subgroup Fluoride supplements
No Fluoride
supplement
prevented
fraction
(SE)
prevented
fraction Weight
prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Lin 2000 (1) 41 17 0.51 (0.216) 28.1 % 0.51 [ 0.09, 0.93 ]
Lin 2000 (2) 40 17 0.81 (0.085) 71.9 % 0.81 [ 0.64, 0.98 ]
Total (95% CI) 81 34 100.0 % 0.73 [ 0.46, 0.99 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.67, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 5.38 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours No F supplements Favours F supplements
(1) NaF tablets
(2) NaF drops
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Analysis 1.6. Comparison 1 Fluoride supplements vs no fluoride supplement, Outcome 6 dmft (24-36
months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 1 Fluoride supplements vs no fluoride supplement
Outcome: 6 dmft (24-36 months)
Study or subgroup Fluoride supplements
No Fluoride
supplement
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Lin 2000 (1) 41 17 0.52 (0.158) 30.9 % 0.52 [ 0.21, 0.83 ]
Lin 2000 (2) 40 17 0.72 (0.106) 34.8 % 0.72 [ 0.51, 0.93 ]
O’Rourke 1988 (3) 285 296 0.13 (0.114) 34.3 % 0.13 [ -0.09, 0.35 ]
Total (95% CI) 366 330 100.0 % 0.46 [ 0.08, 0.83 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 14.54, df = 2 (P = 0.00070); I2 =86%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours No F supplements Favours F supplements
(1) NaF tablets
(2) NaF drops
(3) NaF tablets
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Analysis 2.1. Comparison 2 Fluoride supplements vs Topical Fluoride, Outcome 1 D(MF)S (24-36 months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 2 Fluoride supplements vs Topical Fluoride
Outcome: 1 D(MF)S (24-36 months)
Study or subgroup Fluoride Supplements Topical Fluoride
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Poulsen 1981 (1) 124 125 -0.49 (0.244) 8.4 % -0.49 [ -0.97, -0.01 ]
Heifetz 1987 (2) 372 380 0.11 (0.119) 24.9 % 0.11 [ -0.12, 0.34 ]
Ka¨llest l 2000 (3) 211 228 -0.1 (0.14) 20.1 % -0.10 [ -0.37, 0.17 ]
Holm 1975 (4) 157 200 -0.13 (0.098) 31.1 % -0.13 [ -0.32, 0.06 ]
Poulsen 1981 (5) 129 121 -0.15 (0.167) 15.6 % -0.15 [ -0.48, 0.18 ]
Total (95% CI) 993 1054 100.0 % -0.10 [ -0.25, 0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.81, df = 4 (P = 0.21); I2 =31%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Topical F Favours F supplements
(1) age 7, NaF lozenge vs NaF rinse
(2) NaF tablets vs NaF rinse
(3) NaF lozenges vs NaF varnish
(4) NaF tablets vs NaF rinse
(5) age 11, NaF lozenge vs NaF rinse
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Analysis 2.2. Comparison 2 Fluoride supplements vs Topical Fluoride, Outcome 2 DMFS (48 months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 2 Fluoride supplements vs Topical Fluoride
Outcome: 2 DMFS (48 months)
Study or subgroup Fluoride Supplements Topical Fluoride
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Ka¨llest l 2000 (1) 225 247 0 (0.104) 100.0 % 0.0 [ -0.20, 0.20 ]
Total (95% CI) 225 247 100.0 % 0.0 [ -0.20, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Topical F Favours F supplements
(1) NaF lozenges vs NaF varnish
Analysis 2.3. Comparison 2 Fluoride supplements vs Topical Fluoride, Outcome 3 DMFS (60 months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 2 Fluoride supplements vs Topical Fluoride
Outcome: 3 DMFS (60 months)
Study or subgroup Fluoride Supplements Topical Fluoride
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Ka¨llest l 2000 (1) 213 228 -0.07 (0.11) 47.2 % -0.07 [ -0.29, 0.15 ]
Heifetz 1987 (2) 255 275 0.18 (0.093) 52.8 % 0.18 [ 0.00, 0.36 ]
Total (95% CI) 468 503 100.0 % 0.06 [ -0.18, 0.31 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.01, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Topical F Favours F supplements
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(1) NaF lozenges vs NaF varnish
(2) NaF tablets vs NaF rinse
Analysis 2.4. Comparison 2 Fluoride supplements vs Topical Fluoride, Outcome 4 DMFS (96 months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 2 Fluoride supplements vs Topical Fluoride
Outcome: 4 DMFS (96 months)
Study or subgroup
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
IV,Random,95% CI IV,Random,95% CI
Heifetz 1987 0.21 (0.089) 100.0 % 0.21 [ 0.04, 0.38 ]
Total (95% CI) 100.0 % 0.21 [ 0.04, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Topical F Favours F supplements
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Analysis 2.5. Comparison 2 Fluoride supplements vs Topical Fluoride, Outcome 5 d(m)fs (24-36 months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 2 Fluoride supplements vs Topical Fluoride
Outcome: 5 d(m)fs (24-36 months)
Study or subgroup Fluoride Supplements Topical Fluoride
prevented
fraction
(SE)
prevented
fraction Weight
prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Heifetz 1987 (1) 331 345 0.18 (0.137) 56.3 % 0.18 [ -0.09, 0.45 ]
Petersson 1985 (2) 30 92 -0.06 (0.3) 11.7 % -0.06 [ -0.65, 0.53 ]
Petersson 1985 (3) 30 89 0.1 (0.278) 13.7 % 0.10 [ -0.44, 0.64 ]
Petersson 1985 (4) 30 104 0.14 (0.24) 18.3 % 0.14 [ -0.33, 0.61 ]
Total (95% CI) 421 630 100.0 % 0.13 [ -0.07, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Topical F Favours F supplements
(1) NaF tablets vs NaF rinses
(2) NaF tablets vs NaF toothpaste and varnish
(3) NaF tablets vs NaF toothpaste
(4) NaF tablets vs NaF varnish
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Analysis 3.1. Comparison 3 Fluoride supplements vs other preventive measures, Outcome 1 DMFS
proximal (24-36 months).
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 3 Fluoride supplements vs other preventive measures
Outcome: 1 DMFS proximal (24-36 months)
Study or subgroup (F + xylitol) lozenges xylitol lozenges
Prevented
fraction
(SE)
Prevented
fraction Weight
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
Stecksen-Blicks 2008 (1) 59 56 0 (0.301) 100.0 % 0.0 [ -0.59, 0.59 ]
Total (95% CI) 59 56 100.0 % 0.0 [ -0.59, 0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Xyl Lozenges Favours Xyl + F Lozenges
(1) (xylitol + Fluoride) lozenges vs xylitol lozenges
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Analysis 4.1. Comparison 4 Fluoride supplements vs no fluoride supplement (teeth erupted at baseline or
erupting during the study), Outcome 1 D(M)FS.
Review: Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children
Comparison: 4 Fluoride supplements vs no fluoride supplement (teeth erupted at baseline or erupting during the study)
Outcome: 1 D(M)FS
Study or subgroup Experimental Control
Prevented
fraction
(SE)
Prevented
fraction
Prevented
fraction
N N IV,Random,95% CI IV,Random,95% CI
1 teeth erupted at baseline
Aasenden 1972 (1) 109 70 0.25 (0.089) 0.25 [ 0.08, 0.42 ]
Aasenden 1972 (2) 114 70 0.26 (0.107) 0.26 [ 0.05, 0.47 ]
Driscoll 1974 (3) 202 166 0.06 (0.113) 0.06 [ -0.16, 0.28 ]
Driscoll 1974 (4) 179 91 0.15 (0.084) 0.15 [ -0.01, 0.31 ]
Driscoll 1974 (5) 150 76 0.22 (0.085) 0.22 [ 0.05, 0.39 ]
Driscoll 1974 (6) 168 91 0.26 (0.081) 0.26 [ 0.10, 0.42 ]
Driscoll 1974 (7) 197 166 0.27 (0.092) 0.27 [ 0.09, 0.45 ]
Driscoll 1974 (8) 135 76 0.23 (0.088) 0.23 [ 0.06, 0.40 ]
2 teeth erupting during the study
Aasenden 1972 (9) 109 70 0.4 (0.111) 0.40 [ 0.18, 0.62 ]
Aasenden 1972 (10) 114 70 0.3 (0.115) 0.30 [ 0.07, 0.53 ]
Driscoll 1974 (11) 202 166 0.36 (0.06) 0.36 [ 0.24, 0.48 ]
Driscoll 1974 (12) 179 91 0.42 (0.148) 0.42 [ 0.13, 0.71 ]
Driscoll 1974 (13) 150 76 0.44 (0.104) 0.44 [ 0.24, 0.64 ]
Driscoll 1974 (14) 168 91 0.5 (0.143) 0.50 [ 0.22, 0.78 ]
Driscoll 1974 (15) 187 166 0.27 (0.07) 0.27 [ 0.13, 0.41 ]
Driscoll 1974 (16) 135 76 0.45 (0.109) 0.45 [ 0.24, 0.66 ]
-1 -0.5 0 0.5 1
Favours control/topical F Favours F supplements
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(1) APF tablets (diluted), follow up 36 months
(2) NaF tablets (diluted), follow up 36 months
(3) APF tablets once a day, Follow up 30 months
(4) APF tablets once a day, Follow up 55 months
(5) APF tablets once a day, Follow up 72 months
(6) APF tablets twice a day, Follow up 55 months
(7) APF tablets twice a day, Follow up 30 months
(8) APF tablets twice a day, Follow up 72 months
(9) APF tablets (diluted), follow up 36 months
(10) NaF tablets (diluted), follow up 36 months
(11) APF tablets once a day, Follow up 30 months
(12) APF tablets once a day, Follow up 55 months
(13) APF tablets once a day, Follow up 72 months
(14) APF tablets twice a day, Follow up 55 months
(15) APF tablets twice a day, Follow up 30 months
(16) APF tablets twice a day, Follow up 72 months
A D D I T I O N A L T A B L E S
Table 1. Results of the electronic searches
Database Date Number of reports
MEDLINE via Ovid 12.10.11 1148
CENTRAL 12.10.11 152
OHG Register 12.10.11 264
EMBASE via OVID 12.10.11 248
LILACs/PanAmerican/WHOLIS/
MedCarib
/Brazilian Bibliography of Dentistry
12.10.11 25
Current Controlled Trials 12.10.11 1
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Table 2. Data available in the studies and data used in the analyses
Study Available data Data extracted and used in the analyses
Aasenden 1972 Caries increment (DFS, DFT) after 12, 24, 36
months
Mean and SEM available
Caries increment (DFS, DFT) after 36 months
SD calculated from SEM
Number of controls divided per 2
De Paola 1968 Caries increment (DFS,DFT) after 10 and24months
Mean and SD available
Caries increment (DFS, DFT) after 24 months
Driscoll 1974 Caries increment (DMFS) after 30, 55 and 72months
Caries increment (DMFS) after 30 months given sep-
arately for teeth present at baseline and teeth erupting
during the study
Mean and SEM available
Caries increment (DMFS) after 30 months calculated
by adding caries increment (DMFS) for teeth erupted
at baseline + caries increment (DMFS) for teeth erupt-
ing during the study
Caries increment (DMFS) after 55 months
Caries increment (DMFS) after 72 months
SD calculated with SEM
Number of controls divided per 2
Heifetz 1987 Caries increment (DMFS, dmfs) after 24, 60 and 96
months
Mean and SD available
Caries increment (DMFS, dmfs) after 24, 60 and 96
months
Holm 1975 Caries increment (DS) after 24 months
Mean and SD available
Caries increment (DS) after 24 months
Kallestal 2000 Caries increment (DMFS, DMFSe) after 48 months
Mean and SD available
Mean DMFS, DMFSe (enamel) at baseline
Mean DMFS, DMFSe for each of the 5 years of study
Caries increment (DMFS) after 48 months
Calculation of caries increment (DMFS) after 24 and
60 months by subtracting baseline DMFS to final
DMFS
SD estimated
24months = length close/other follow-ups in the same
comparison group
Lin 2000 Caries increment (dmft, dmfs) after 24 months
Mean and SD available
Caries increment (dmft, dmfs) after 24 months
Number of controls divided per 2
77Fluoride supplements (tablets, drops, lozenges or chewing gums) for preventing dental caries in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Data available in the studies and data used in the analyses (Continued)
O Rourke 1988 Caries increment (dmft, DMFT ) after 12, 24, 36
months
Mean and SD available
Caries increment (dmft, DMFT) after 24 months
24 months = length close to other follow-ups in the
same comparison group
Petersson 1985 Caries increment (ds) after 12 and 24 months
Mean available, SD not available
Caries increment (ds) after 24 months
SD estimated
Number of controls divided per 3
Poulsen 1981 Caries increment (DMFS) after 36 months
Caries increment (DMFS) given per age (7, 11 years)
and separately for teeth erupted at baseline or for teeth
erupting during the study
Mean available, SD not available
Caries increment (DMFS) calculated by adding caries
increment (DMFS) for teeth erupted at baseline and
caries increment (DMFS) for teeth erupting during
the study
Caries increment (DMFS) calculated separately per
age (7, 11 years)
SD estimated
Stecksen Blicks 2008 Caries increment (DMFSa: approximal caries and
DSe: enamel lesions on approximal surfaces) after 24
months
Mean and SD available
Caries increment (DMFSa) after 24 months
A P P E N D I C E S
Appendix 1. MEDLINE via OVID Search Strategy
1. exp Tooth demineralization/
2. Dental caries activity tests/
3. Dental caries susceptibility/
4. Dental enamel solubility/
5. ((teeth or tooth or dental or dentin or enamel or root$ or rampant or recur$) adj5 (cavit$ or caries or carious or decay$)).mp.
6. (DMF or DFS or DFT or DMFT).ti,ab.
7. DMF Index/
8. ((tooth or teeth or enamel or dentin or root$) adj5 (deminerali$ or reminerali$)).mp. [mp=title, original title, abstract, name of
substance word, subject heading word, unique identifier]
9. or/1-8
10. exp Fluorides/
11. Cariostatic agents/
12. (fluoride$ or cariostat$).mp.
13. (fluoride$ and (tablet$ or drop$ or lozenge$ or pill$ or “chewing gum$” or supplement$)).mp.
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14. or/10-12
15. 13 and 14
16. 9 and 15
Appendix 2. EMBASE via OVID SEARCH STRATEGY
1. exp Tooth demineralization/
2. Dental caries activity tests/
3. Dental caries susceptibility/
4. Dental enamel solubility/
5. ((teeth or tooth or dental or dentin or enamel or root$ or rampant or recur$) adj5 (cavit$ or caries or carious or decay$)).mp.
6. (DMF or DFS or DFT or DMFT).ti,ab.
7. DMF Index/
8. ((tooth or teeth or enamel or dentin or root$) adj5 (deminerali$ or reminerali$)).mp.
9. or/1-8
10. exp Fluorides/
11. Cariostatic agents/
12. (fluoride$ or cariostat$).mp.
13. (fluoride$ and (tablet$ or drop$ or lozenge$ or pill$ or “chewing gum$” or supplement$)).mp.
14. or/10-12
15. 13 and 14
Appendix 3. LILACS/PanAmerican/WHOLIS/MedCarib/BBO Search Strategy
teeth or tooth or dental or dentin$ or enamel or root$ or rampant or recur$) [Words] and (cavit$ or caries or carious or decay$) [Words]
and (fluoride$ and (tablet$ or drop$ or lozenge$ or pill$ or “chewing gum” or supplement$))
Appendix 4. CENTRAL Search Strategy
#1 MeSH descriptor Tooth Demineralization explode all trees
#2 MeSH descriptor Dental Caries Activity Tests explode all trees
#3 MeSH descriptor Dental Caries Susceptibility explode all trees
#4 MeSH descriptor Dental Enamel Solubility explode all trees
#5 ((tooth in All Text or teeth in All Text or dental* in All Text or dentin* in All Text or enamel in All Text or root* in All Text or
rampant in All Text or recur* in All Text) and (cavit* in All Text or caries in All Text or carious in All Text or decay* in All Text))
#6 (DMF in Title, Abstract or Keywords or DFS in Title, Abstract or Keywords or DFT in Title, Abstract or Keywords or DMFT
in Title, Abstract or Keywords)
#7 ((deminerali* in All Text or reminerali* in All Text) and (tooth in All Text or teeth in All Text or enamel in All Text or dentin*
in All Text or root* in All Text))
#8 MeSH descriptor DMF Index explode all trees
#9 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
#10 MeSH descriptor Fluorides explode all trees
#11 MeSH descriptor Cariostatic Agents explode all trees
#12 fluoride* in All Text
#13 cariostat* in All Text
#14 (fluoride* in All Text and (tablet* in All Text or drop* in All Text or lozenge* in All Text or pill* in All Text or “chewing gum”
in All Text))
#15 (fluoride* in All Text and supplement* in All Text)
#16 (#10 or #11 or #12 or #13)
#17 (#14 or #15)
#18 (#9 and (#16 and #17))
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Appendix 5. OHG TRIALS REGISTER SEARCH STRATEGY
(fluoride* AND (supplement* or tablet* or drop* or lozenge* or pill* or “chewing gum*”))
Appendix 6. Current Controlled Trials Search Strategy
(fluoride% and (tablet% or drop% or lozenge% or pill% or “chewing gum”))
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• British Orthodontic Society (BOS), UK.
The BOS have provided funding for the Cochrane Oral Health Group Global Alliance (see www.ohg.cochrane.org)
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The paragraph ’statistical analysis’ in the method section (Data collection and analysis) has been rewritten in view of the analyses that
were effectively conducted.
Two authors have been added and the order of citation was changed in view of the actual participation of each author.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Capsules; Cariostatic Agents [∗administration & dosage]; Chewing Gum; Dental Caries [∗prevention & control]; Fluorides
[∗administration & dosage]; Randomized Controlled Trials as Topic; Tablets
MeSH check words
Child; Child, Preschool; Humans
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